<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2412200362
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Borvix
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BORTEZOMIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2177.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Qilu Pharmaceutical Hainan Co Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Qilu Pharmaceutical Hainan Co Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX32
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BORVIX contains the active substance bortezomib, a so-called &lsquo;proteasome inhibitor&rsquo;. Proteasomes play an important role in controlling cell function and growth. By interfering with their function, bortezomib can kill cancer cells.</p><p>BORVIX is used for the treatment of multiple myeloma (a cancer of the bone marrow) in patients older than 18 years:</p><p>- alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.</p><p>- in combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation.</p><p>- in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment).</p><p>&nbsp;</p><p>BORVIX is used for the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously treated and for whom blood stem cell transplantation is unsuitable.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use BORVIX </strong></p><p>- if you are allergic to bortezomib, boron or to any of the other ingredients of this medicine (listed in section 6)</p><p>- if you have certain severe lung or heart problems.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>You should tell your doctor if you have any of the following:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;low numbers of red or white blood cells</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;bleeding problems and/or low number of platelets in your blood</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, constipation, nausea or vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, dizziness or light-headedness in the past</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moderate to severe liver problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness, tingling, or pain in the hands or feet (neuropathy) in the past</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart or blood pressure problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath or cough</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shingles (localised including around the eyes or spread across the body)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of tumor lysis syndrome such as muscle cramping, muscle weakness, confusion, visual loss or disturbances and shortness of breath</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; memory loss, trouble thinking, difficulty with walking or loss of vision. These may be signs of a serious brain infection and your doctor may suggest further testing and follow-up.</p><p>&nbsp;</p><p>You will have to take regular blood tests before and during your treatment with BORVIX, to check your blood cell counts regularly.</p><p>If you have mantle cell lymphoma and are given the medicine rituximab with BORVIX you should tell your doctor:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you think you have hepatitis infection now or have had it in the past. In a few cases, patients who have had hepatitis B might have a repeated attack of hepatitis, which can be fatal. If you have a history of hepatitis B infection you will be carefully checked by your doctor for signs of active hepatitisB.</p><p>&nbsp;</p><p>You must read the package leaflets of all medicinal products to be taken in combination with BORVIX for information related to these medicines before starting treatment with BORVIX. When thalidomide is used, particular attention to pregnancy testing and prevention requirements is needed (see Pregnancy and breast-feeding in this section).</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>BORVIX should not be used in children and adolescents because it is not known how the medicine will affect them.</p><p>&nbsp;</p><p><strong>Other medicines and BORVIX </strong></p><p>Please tell your doctor, or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor if you are using medicines containing any of the following active substances:</p><p>- ketoconazole, used to treat fungal infections</p><p>ritonavir, used to treat HIV infection</p><p>- rifampicin, an antibiotic used to treat bacterial infections</p><p>- carbamazepine, phenytoin or phenobarbital used to treat epilepsy</p><p>- St. John&rsquo;s Wort (<em>Hypericum perforatum</em>), used for depression or other conditions</p><p>- oral antidiabetics</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>You should not use BORVIX if you are pregnant, unless clearly necessary.</p><p>Both men and women receiving BORVIX must use effective contraception during and for up to 3 months after treatment. If, despite these measures, pregnancy occurs, tell your doctor immediately.</p><p>You should not breast-feed while using BORVIX. Discuss with your doctor when it is safe to restart breast-feeding after finishing your treatment.</p><p>Thalidomide causes birth defects and foetal death. When BORVIX is given in combination with thalidomide you must follow the pregnancy prevention programme for thalidomide (see package leaflet for thalidomide).</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>BORVIX might cause tiredness, dizziness, fainting, or blurred vision. Do not drive or operate tools or machines if you experience such side effects; even if you do not, you should still be cautious.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will work out your dose of BORVIX according to your height and weight (body surface area). The usual starting dose of BORVIX is 1.3 mg/m2 body surface area twice a week.</p><p>Your doctor may change the dose and total number of treatment cycles, depending on your response to the treatment on the occurrence of certain side effects and on your underlying conditions (e.g. liver problems).</p><p><em>Progressive multiple myeloma </em></p><p>When BORVIX is given alone, you will receive 4 doses of BORVIX intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a 10-day &lsquo;rest period&rsquo; without treatment. This 21-day period (3 weeks) corresponds to one treatment cycle. You might receive up to 8 cycles (24 weeks).</p><p>You may also be given BORVIX together with the medicines pegylated liposomal doxorubicin or dexamethasone.</p><p>When BORVIX is given together with pegylated liposomal doxorubicin, you will receive BORVIX intravenously or subcutaneously as a 21-day treatment cycle and pegylated liposomal doxorubicin 30 mg/m2 is given on day 4 of the BORVIX 21-day treatment cycle as an intravenous infusion after the BORVIX injection.</p><p>You might receive up to 8 cycles (24 weeks).</p><p>When BORVIX is given together with dexamethasone, you will receive BORVIX intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 20 mg is given orally on days 1, 2, 4, 5, 8, 9, 11, and 12, of the BORVIX, 21-day treatment cycle.</p><p>You might receive up to 8 cycles (24 weeks).</p><p><em>Previously untreated multiple myeloma </em></p><p>If you have not been treated before for multiple myeloma, and <strong>you are not </strong>suitable for blood stem cell transplantation you will receive BORVIX together with two other medicines; melphalan and prednisone.</p><p>In this case, the duration of a treatment cycle is 42 days (6 weeks). You will receive 9 cycles (54 weeks).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;In cycles 1 to 4, BORVIX is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;In cycles 5 to 9, BORVIX is administered once weekly on days 1, 8, 22 and 29.</p><p>&nbsp;</p><p>Melphalan (9 mg/m2) and prednisone (60 mg/m2) are both given orally on days 1, 2, 3 and 4 of the first week of each cycle.</p><p>If you have not been treated before for multiple myeloma, and <strong>you are </strong>suitable for blood stem cell transplantation you will receive BORVIX intravenously or subcutaneously together with the medicines dexamethasone, or dexamethasone and thalidomide, as induction treatment.</p><p>When BORVIX is given together with dexamethasone, you will receive BORVIX intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the BORVIX 21-day treatment cycle.</p><p>You will receive 4 cycles (12 weeks).</p><p>When BORVIX is given together with thalidomide and dexamethasone, the duration of a treatment cycle is 28 days (4 weeks).</p><p>Dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the BORVIX 28-day treatment cycle and thalidomide is given orally daily at 50 mg up to day 14 of the first cycle, and if tolerated the thalidomide dose is increased to 100 mg on days 15-28 and may be further increased to 200 mg daily from the second cycle onwards.</p><p>You might receive up to 6 cycles (24 weeks).</p><p><em>Previously untreated mantle cell lymphoma </em></p><p>If you have not been treated before for mantle cell lymphoma you will receive BORVIX intravenously or subcutaneously together with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone.</p><p>BORVIX is given intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a &lsquo;rest period&rsquo; without treatment. The duration of a treatment cycle is 21 days (3 weeks). You might receive up to 8 cycles (24 weeks).</p><p>The following medicinal products are given on day 1 of each BORVIX 21-day treatment cycle as intravenous infusions:</p><p>Rituximab at 375 mg/m2, cyclophosphamide at 750 mg/m2 and doxorubicin at 50 mg/m2.</p><p>Prednisone is given orally at 100 mg/m2 on days 1, 2, 3, 4 and 5 of the BORVIX treatment cycle.</p><p>&nbsp;</p><p><strong>How BORVIX is given </strong></p><p>This medicine is for intravenous or subcutaneous use. BORVIX will be administered by a health care professional experienced in the use of cytotoxic medicines.</p><p>BORVIX Lyophilized powder has to be dissolved before administration. This will be done by a healthcare professional. The resulting solution is then either injected into a vein or under the skin. Injection into a vein is rapid, taking 3 to 5 seconds. Injection under the skin is in either the thighs or the abdomen.</p><p>&nbsp;</p><p><strong>If you are given too much BORVIX </strong></p><p>As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much. In the unlikely event of an overdose, your doctor will monitor you for side effects.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these effects may be serious.</p><p>If you are given BORVIX for multiple myeloma or mantle cell lymphoma, tell your doctor straight away if you notice any of the following symptoms:</p><p>- muscle cramping, muscle weakness</p><p>- confusion, visual loss or disturbances, blindness, seizures, headaches</p><p>- shortness of breath, swelling of your feet or changes in your heart beat, high blood pressure, tiredness, fainting</p><p>- coughing and breathing difficulties or tightness in the chest.</p><p>Treatment with BORVIX can very commonly cause a decrease in the numbers of red and white blood cells and platelets in your blood. Therefore, you will have to take regular blood tests before and during your treatment with BORVIX, to check your blood cell counts regularly. You may experience a reduction in the number of:</p><p>- platelets, which may make you be more prone to bruising, or to bleeding without obvious injury (e.g., bleeding from your bowels, stomach, mouth and gum or bleeding in the brain or bleeding from the liver)</p><p>- red blood cells, which can cause anaemia, with symptoms such as tiredness and paleness</p><p>- white blood cells may make you more prone to infections or flu-like symptoms.</p><p>If you are given BORVIX for the treatment of multiple myeloma the side effects you may get are listed below:</p><p><strong>Very common side effects (may affect more than 1 in 10 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet, due to nerve damage</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in the number of red blood cells and or white blood cells (see above)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea) or vomiting, loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation with or without bloating (can be severe)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea: if this happens, it is important that you drink more water than usual. Your doctor may give you another medicine to control diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness (fatigue), feeling weak</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain, bone pain</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure, sudden fall of blood pressure on standing which may lead to fainting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced functioning of your kidneys</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General ill feeling, pain, vertigo, light-headedness, a feeling of weakness or loss of consciousness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shivering</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections, including pneumonia, respiratory infections, bronchitis, fungal infections, coughing with phlegm, flu like illness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles (localised including around the eyes or spread across the body)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pains or shortness of breath with exercise</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Different types of rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching of the skin, lumps on the skin or dry skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Facial blushing or tiny broken capillaries</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartburn, bloating, belching, wind, stomach pain, bleeding from your bowels or stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alteration of liver functioning</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A sore mouth or lip, dry mouth, mouth ulcers or throat pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss, loss of taste</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps, muscle spasms, muscle weakness, pain in your limbs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the outermost layer of the eye and the inner surface of the eyelids (conjunctivitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nose bleeds</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty or problems in sleeping, sweating, anxiety, mood swings, depressed mood, restlessness or agitation, changes in your mental status, disorientation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of body, to include around eyes and other parts of the body</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure, heart attack, chest pain, chest discomfort, increased or reduced heart rate</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Failing of your kidneys</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of a vein, blood clots in your veins and lungs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with blood clotting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insufficient circulation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the lining around your heart or fluid around your heart</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections including urinary tract infections, the flu, herpes virus infections, ear infection and cellulitis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bloody stools, or bleeding from mucosal membranes, e.g., mouth, vagina</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cerebrovascular disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paralysis, seizures, falling, movement disorders, abnormal or change in, or reduced sensation (feeling, hearing, tasting, smelling), attention disturbance, trembling, twitching</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthritis, including inflammation of the joints in the fingers, toes, and the jaw</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorders that affect your lungs, preventing your body from getting enough oxygen. Some of these include difficulty breathing, shortness of breath, shortness of breath without exercise, breathing that becomes shallow, difficult or stops, wheezing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hiccups, speech disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased or decreased urine production (due to kidney damage), painful passing of urine or blood/proteins in the urine, fluid retention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Altered levels of consciousness, confusion, memory impairment or loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing loss, deafness or ringing in the ears, ear discomfort</p><p>Hormone abnormality which may affect salt and water absorption</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overactive thyroid gland</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to produce enough insulin or resistance to normal levels of insulin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritated or inflamed eyes, excessively wet eyes, painful eyes, dry eyes, eye infections, lump in the eyelid (chalazion), red and swollen eyelids, discharge from the eyes, abnormal vision, bleeding of the eye</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of your lymph glands</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint or muscle stiffness, sense of heaviness, pain in your groin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss and abnormal hair texture</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness or pain at the injection site</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections or inflammation of the mouth, mouth ulcers, oesophagus, stomach and intestines, sometimes associated with pain or bleeding, poor movement of the intestines (including blockage), abdominal or oesophageal discomfort, difficulty swallowing, vomiting of blood</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial and viral infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tooth infection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas, obstruction of the bile duct</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genital pain, problem having an erection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight increase</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thirst</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site or injection device related disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions and disorders (which may be severe and life threatening), skin ulcers</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruises, falls and injuries</p><p dir="RTL">Inflammation or haemorrhage of the blood vessels that can appear as small red or purple dots (usually on the legs) to large bruise-like patches under the skin or tissue Benign cysts</p><p dir="RTL">A severe reversible brain condition which includes seizures, high blood pressure, headaches, tiredness, confusion, blindness or other vision problems. <strong>Rare side effects (may affect up to 1 in 1,000 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart problems to include heart attack, angina</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discoloration of the veins</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the spinal nerve</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with your ear, bleeding from your ear</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Underactivity of your thyroid gland</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Budd&ndash;Chiari syndrome (the clinical symptoms caused by blockage of the hepatic veins)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in or abnormal bowel function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding in the brain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow discolouration of eyes and skin (jaundice)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction (anaphylactic shock) signs of which may include difficulty breathing, chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal tears</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genital swelling</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to tolerate alcohol consumption</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wasting, or loss of body mass</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fistula</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint effusion</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cysts in the lining of joints (synovial cysts)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fracture</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breakdown of muscle fibers leading to other complications</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the liver, bleeding from the liver</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer of the kidney</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psoriasis like skin condition</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paleness of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of platelets or plasma cells (a type of white cell) in the blood</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clot in small blood vessels (thrombotic microangiopathy)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal reaction to blood transfusions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial or total loss of vision</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased sex drive</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drooling</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bulging eyes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensitivity to light</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rectal pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gallstones</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hernia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injuries</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brittle or weak nails</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal protein deposits in your vital organs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coma</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intestinal ulcers</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Multi-organ failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Death If you are given BORVIX together with other medicines for the treatment of mantle cell lymphoma the side effects you may get are listed below:</p><p><strong>Very common side effects (may affect more than 1 in 10 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet, due to nerve damage</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea and vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth ulcers</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Muscle pain, bone pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Hair loss and abnormal hair texture</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness, feeling weak</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p dir="RTL"><strong>Common side effects (may affect up to 1 in 10 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles (localized including around the eyes or spread across the body)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Herpes virus infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial and viral infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory infections, bronchitis, coughing with phlegm, flu like illness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity (allergic reaction)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to produce enough insulin or resistance to normal levels of insulin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid retention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty or problems in sleeping</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of conciousness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Altered level of consciousness, confusion</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased heartbeat, high blood pressure, sweating,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal vision, blurred vision</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure, heart attack, chest pain, chest discomfort, increased or reduced heart rate</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High or low blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden fall of blood pressure upon standing which may lead to fainting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath with exercise</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hiccups</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing in the ears, ear discomfort</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding from your bowels or stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartburn</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain, bloating</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty swallowing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection or inflammation of the stomach and intentines</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore mouth or lip, throat pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alteration of liver function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching of skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasms</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the urinary tract</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in limbs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of body, to include eyes and other parts of the body</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shivering</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness and pain at injection site</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General ill feeling</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight increase</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction (anaphylactic reaction) signs of which may include difficulty breathing, chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Movement disorders, paralysis, twitching</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing loss, deafness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorders that affect your lungs, preventing your body from getting enough oxygen. Some of these include difficulty breathing, shortness of breath, shortness of breath without exercise, breathing that becomes shallow, difficult or stops, wheezing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in your lungs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow discoloration of the eyes and skin (jaundice)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lump in the eyelid (chalazion), red and swollen eyelidsRare side effects (may affect up to 1 in 1,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clot in small blood vessels (thrombotic microangiopathy)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date stated on the vial and the carton after EXP.</p><p>Store below 25 C</p><p>Store in the original package in order to protect from light.</p><p>The reconstituted solution should be used immediately after preparation. If the reconstituted solution is not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. However, the reconstituted solution is stable for 8 hours at 25&deg;C stored in the original vial and/or a syringe, with a total storage time for the reconstituted medicine not exceeding 8 hours prior to administration.</p><p>BORVIX is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is bortezomib. Each vial contains 3.5 mg of bortezomib (as a mannitol boronic ester).</p><p>- The other ingredients are mannitol (E421) , Tert butyl alcohol and nitrogen.</p><p>Intravenous reconstitution:</p><p>After reconstitution, 1 ml of solution for intravenous injection contains 1 mg bortezomib.</p><p>Subcutaneous reconstitution:</p><p>After reconstitution, 1 ml of solution for subcutaneous injection contains 2.5 mg bortezomib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                BORVIX Lyophilized powder for solution for injection is a white to off-white cake or powder. 
Each carton of BORVIX 3.5 mg Lyophilized powder for solution for injection contains 10 mL type I glass vial with a 13 mm rubber stopper and a 13 mm aluminum-plastic cap.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>Manufacturer by: </strong></p><p>Qilu Pharmaceutical (Hainan) Co., Ltd.- China for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nov-19
SPM190547

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بورﭬيكس على المادة الفعّالة بورتيزوميب، والتي تُعرَف بــ &quot;مثبط إنزيم البروتياز&quot;.&nbsp; تلعب البروتيزومات دورًا مهما في التحكم في وظائف الخلايا ونموّها. وبالتدخل في وظائف تلك الخلايا، فيُمكن أن يقتل دواء بورتيزوميب الخلايا السرطانية.</p><p dir="RTL">يستخدم بورﭬيكس لعلاج الورم النخاعي المتعدد (سرطان النخاع العظمي) لمن تزيد أعمارهم عن 18 عامًا من المرضى:</p><p dir="RTL">-&nbsp;&nbsp; وذلك بمفرده أو بالإضافة إلى أدوية تحتوي على البولي إيثيلين جلايكول أو ديكساميثازون، لـلمرضى الذين تتدهور حالتهم (تدريجيًا) عقب تناولهم علاجًا واحدًا على الأقل، أو كانت عملية زرع الخلايا الجذعية لهم غير ناجحة أو لم تناسبهم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلى جانب أدوية ملفلان وبريدنيزون، للمرضى الذين لم يتلقوا علاجًا من قبل، ولا يُناسبهم تناول جرعات عالية من العلاج الكيميائي، بالنسبة لعملية زرع الخلايا الجذعية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلى جانب أدوية ديكساميثازون أو ديكساميثازون مع لثاليدوميد، وذلك للمرضى الذين لم يتلقوا علاجًا من قبل، وقبل تناول الجرعة العالية من العلاج الكيميائي، وذلك بالنسبة لعملية زرع الخلايا الجذعية (العلاج بالحث).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم بورﭬيكس لعلاج سرطان الغدد الليمفاوية (نوع من السرطان يُصيب الغدد الليمفاوية) للمرضى الذين تبلُغ أعمارهم 18 عامًا أو أكثر، بالإضافة إلى أدوية ريتوكسيماب، وسيكلوفوسفاميد، ودوكسوروبيسين، وبريدنيزون، وذلك للمرضى الذين لم يتلقوا علاجًا من قبل، ولا تناسبهم عملية زرع الخلايا الجذعية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما هي المعلومات التي يجب معرفتها قبل تناول بورﭬيكس</p><p>لا تتناول بورﭬيكس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من حساسية مُفرطة لمادة البورتيزوميب، أو لأي مكوّنات أخرى في هذا الدواء (من المكونات المذكورة في الفقرة رقم 6)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من بعض المشاكل الحادة في الرئة أو القلب.</p><p dir="RTL">&nbsp;</p><p>التحذيرات والاحتياطات</p><p dir="RTL">يجب إبلاغ الطبيب على الفور إذا عانيت من أي من الأعراض التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد خلايا الدم الحمراء أو البيضاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة النزيف و/أو نقص عدد الصفائح الدموية لديك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال أو الإمساك أو الغثيان أو القيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء أو الدوار أو الشعور بالدوخة سابقًا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكبد تتراوح ما بين المستوى المتوسط والحاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الحسّ، أو التنميل أو ألم في اليدين أو القدمين (الاعتلال العصبي) سابقًا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في ضغط الدم أو القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس أو السعال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهريس النطاقي / الحزام الناري (الذي يتواجد أو ينتشر حول العينين أو في جميع أنحاء الجسم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض متلازمة انحلال الورم، مثل: التشنّجات العضلية، أو ضعف العضلات، أو الاختلاط العقلي، أو فقدان البصر، أو الاضطرابات النفسية، أو ضيق في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة، أو مشاكل في التفكير، أو صعوبة في المشي، أو فقدان البصر. حيثُ تكون هذه إشارات إلى وجود عدوى خطيرة بالمخ، وقد يقترح طبيبك إجراء المزيد من الفحوصات والمتابعة.</p><p dir="RTL">يجب عليك إجراء اختبارات فحص الدم بشكل منتظم قبل وأثناء تناولك دواء بورﭬيكس، للتحقق من انتظام عدد خلايا الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجي إبلاغ طبيبك، إذا كنت تُعاني من سرطان الغدد الليمفاوية، وتناولت دواء ريتوكسيماب بالإضافة إلى بورﭬيكس:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشعر بأنك تُعاني من عدوى التهاب الكبد في الوقت الحالي أو سابقًا.&nbsp; وفي بعض الحالات، قد يتعرّض المرضى ممن أصيبوا بفيروس التهاب الكبد &quot;ب &quot; لتكرار الإصابة بالعدوى مرة أخرى، التي يمكن أن تكون مميتة.&nbsp; إذا كان لديك تاريخ مرضى سابق مع فيروس التهاب الكبد &quot;ب &quot;، فسيُجرى لك الطبيب الفحص بعناية بحثًا عن علامات على وجود فيروس التهاب الكبد &quot;ب &quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى قراءة هذه النشرة الدوائية لجميع المنتجات الطبيّة التي ينبغي تناولها مع بورﭬيكس، للاطلاع على المعلومات المتعلقة بهذه الأدوية قبل بدء تناول دواء بورﭬيكس. عند تناولك ثاليدوميد، يُرجى الاهتمام بمتطلبات اختبارات الحمل والوقاية بصورة خاصة، (يُرجى الاطلاع على القسم الخاص بالحمل والرضاعة الطبيعية في هذه الفقرة).</p><p dir="RTL">&nbsp;</p><p>الأطفال والمراهقون</p><p dir="RTL">يجب عدم استخدام بورﭬيكس للأطفال والمراهقين حيث أن تأثير الدواء عليهم غير معروف.</p><p dir="RTL">&nbsp;</p><p>تناول أدوية أخرى مع دواء بورﭬيكس</p><p dir="RTL">يجب عليك إخبار الطبيب أو الصيدليّ إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر.</p><p dir="RTL">وعلى وجه التحديد، يجب إخبار الطبيب إذا كنت تتناول أي من الأدوية التي تحتوي على المواد التالية</p><p dir="RTL">المواد:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء كيتوكونازول، يُستخدم لمعالجة الالتهابات الفطرية وفيروس نقص المناعة البشرية</p><p dir="RTL">-&nbsp;&nbsp; دواء ريفامبيسين وهو مضاد حيوي يستخدم في الالتهابات البكتيرية</p><p dir="RTL">-&nbsp;&nbsp; أدوية كاربامازيبين أو فينيتوين أو فينوباربيتال المستخدمة لعلاج الصرع</p><p dir="RTL">-&nbsp;&nbsp; هايبيريكم بيرفراتم الذي يستخدم لعلاج الاكتئاب والحالات الأخرى</p><p dir="RTL">-&nbsp;&nbsp; المضادات الحيوية الفموية</p><p dir="RTL">&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL">لا يستخدم بورﭬيكس مع الحمل إلا في حالات الضرورة القصوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتعين على الرجال والسيدات الذين يتناولون بورﭬيكس استخدام وسائل منع الحمل الفعالة خلال مدة تصل إلى 3 أشهر بعد العلاج</p><p dir="RTL">وفي حالة حدوث حمل، بالرغم من هذه التدابير، يجب إخبار الطبيب على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب التوقف عن الرضاعة الطبيعية خلال فترة تناول بورﭬيكس. يتعين التحدث مع الطبيب عندما يكون من الآمن إعادة الرضاعة الطبيعية بعد الانتهاء من العلاج</p><p dir="RTL">&nbsp;</p><p dir="RTL">يسبب دواء ثاليدوميد عيوب خلقية ووفاة جنينية. عند تناول بورﭬيكس مع ثاليدوميد، يجب متابعة برنامج الوقاية من الحمل للثاليدومايد (انظر نشرة العبوة الخاصة بالثاليدومايد).</p><p dir="RTL">&nbsp;</p><p>القيادة واستخدام الآلات</p><p dir="RTL">قد يسبب بورﭬيكس الإرهاق أو الدوخة أو الإغماء أو عدم وضوح الرؤية. ينبغي عدم القيادة أو تشغيل أدوات أو آلات إذا واجهت هذه الآثار الجانبية حتى لو لم تفعل، يجب الحذر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيعلمك طبيبك بالجرعة المناسبة لك وفق طولك ووزنك (مساحة سطح الجسم). وغالبًا ما تكون الجرعة الأولية لبورﭬيكس 1.3 ملغم/متر <sup>2</sup> من مساحة الجسم مرتين في الأسبوع.</p><p dir="RTL">ربما يقوم طبيبك بتغيير جرعتك وعدد دورات العلاج بناء على مدى استجابتك للعلاج من حيث ظهور آثار جانبية محددة ووضعك الصحي (مثل وجود مشاكل في الكبد على سبيل المثال).</p><p dir="RTL">الورم النقوي المتعدد</p><p dir="RTL">عند تلقيك العلاج ببورﭬيكس بمفرده، سيتم حقنك بـ 4 جرعات منه عن طريق الوريد أو تحت الجلد في الأيام 1 و4 و8 و11 وتتبعها 10 أيام راحة من العلاج. تتكون دورة العلاج الواحدة من 21 يوم (3 أسابيع). يمكنك أن تأخذ حتى 8 دورات من العلاج (24 أسبوع).</p><p dir="RTL">يمكنك العلاج ببورﭬيكس بالإضافة إلى أدوية تحتوي على البولي إيثيلين جلايكول أو الدوكسوروبيسين أو الديكساميثازون.&nbsp;</p><p dir="RTL">عند تناول دواء بورﭬيكس مع البولي إيثيلين جلايكول، سيحقن بورﭬيكس عن طريق الوريد أو تحت الجلد بمدة دورة علاج تبلغ 21 يوم ويتم تناول30 ملغم/متر <sup>2</sup> من البولي إيثيلين جلايكول في اليوم الرابع من دورة العلاج ببورﭬيكس (21 يوم) عن طريق التسريب الوريدي بعد الحقن ببورﭬيكس.</p><p dir="RTL">يمكنك أن تأخذ حتى 8 دورات من العلاج (24 أسبوع).</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يتم تناول بورﭬيكس مع دواء الديكساميثازون، سيتم حقنه عن طريق الوريد أو تحت الجلد بمدة دورة علاج تبلغ 21 يوم ويتم تناول20 ملغم من ديكساميثازون عن طريق الفم في الأيام 1 و2 و4 و5 و8 و9 و11 و12 من دورة العلاج ببورﭬيكس والتي تستمر 21 يومًا.</p><p dir="RTL">يمكنك أن تأخذ حتى 8 دورات من العلاج (24 أسبوع).</p><p dir="RTL">&nbsp;</p><p dir="RTL">الورم النقوي المتعدد غير المعالج سابقًا</p><p dir="RTL">إذا لم تتعالج من قبل من الورم النقوي المتعدد <strong>ولا تناسبك</strong> عملية زرع الخلايا الجذعية، ستتناول بورﭬيكس إلى جانب دوائيين أخرين وهم ملفلان وبريدنيزون.</p><p dir="RTL">وفي هذه الحالة ستكون مدة دورة العلاج 42 يومًا (6 أسابيع).&nbsp; ستأخذ 9 دورات من العلاج (54 أسبوع).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تناول بورﭬيكس مرتين في الأسبوع وذلك في الدورة 1 وحتى الدورة 4 في أيام 1 و4 و8 و11 و22 و25 و29 و32.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تناول بورﭬيكس مرة أسبوعيًا وذلك في الدورة 5 وحتى الدورة 9 في أيام1 و8 و22 و29. يتم تناول دواء ملفلان (9 ملغم/متر 2) وبريدنيزون (60ملغم/متر<sup>2</sup>) عن طريق الفم في الأيام 1 و2 و3 و4 في أول أسبوع من بداية كل دورة علاجية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تتعالج من قبل من الورم النقوي المتعدد <strong>ولا تناسبك</strong> عملية زرع الخلايا الجذعية، ستحقن ببورﭬيكس عن طريق الوريد أو تحت الجلد وذلك إلى جانب تناول أدوية أخري وهي ديكساميثازون أو ديكساميثازون وثاليدوميد كعلاج بالحث.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يتم تناول بورﭬيكس مع دواء الديكساميثازون، سيتم حقنه عن طريق الوريد أو تحت الجلد لمدة 21 يوم وتناول ديكساميثازون بجرعة 40 ملغم تُؤخذ عن طريق الفم في الأيام 1 و2 و3 و4 و8 و9 و10 و11من دورة العلاج ببورﭬيكس والتي تستمر 21 يومًا.</p><p dir="RTL">ستتلقى4 دورات من العلاج (12 أسبوع).</p><p dir="RTL">عندما يتم تناول بورﭬيكس مع دواء الثاليدوميد والديكساميثازون ستكون مدة العلاج 28 يوم (4أسابيع).</p><p dir="RTL">يتم تناول40 ملغم من دواء الديكساميثازون عن طريق الفم في الأيام 1 و2 و3 و4 و8 و9 و10 و11 من دورة العلاج ببورﭬيكس (28 يوم) وتناول50 ملغم من الثاليدوميد عن طريق الفم يومًا وحتى يوم 14 من الدورة الأولى وإذا تحمل المريض العلاج، يتم زيادة جرعة الثاليدوميد إلى 100 ملغم في الأيام 15-28 ويمكن زيادتها أكثر حتى تصل إلى 200 ملغم يوميًا بدء من دورة العلاج الثانية فصاعدًا.</p><p dir="RTL">يمكنك أن تأخذ حتى 6 دورات من العلاج (24 أسبوع).</p><p dir="RTL">سرطان الغدد الليمفاوية غير المعالج سابقًا</p><p dir="RTL">إذا لم تتعالج سابقًا من سرطان الغدد الليمفاوية، ستحقن ببورﭬيكس عن طريق الوريد أو تحت الجلد وذلك إلى جانب أدوية ريتوكسيماب وسيكلوفوسفاميد</p><p dir="RTL">&nbsp;الدوكسوروبيسين وبريدنيزون.</p><p dir="RTL">يُحقن بورﭬيكس عن طريق الوريد أو تحت الجلد في الأيام 1 و4 و8 و11 وتتبعها &quot;فترة راحة&quot; من العلاج.&nbsp; مدة العلاج 21 يومًا (3 أسابيع). يمكنك أن تأخذ حتى 8 دورات من العلاج (24 أسبوع).</p><p dir="RTL">يتم تناول هذه المنتجات الدوائية كتسريبات وريدية في اليوم الأول من كل دورة للعلاج ببورﭬيكس (21 يوم):</p><p dir="RTL">ريتوكسيماب بجرعة 375 ملغم/متر <sup>2</sup> وسيكلوفوسفاميد بجرعة 750 ملغم/متر <sup>2</sup> ودوكسوروبيسين بجرعة 50 ملغم/متر <sup>2</sup>.&nbsp; يُتناول البريدنيزون عن طريق الفم بجرعة 100 ملغم /متر <sup>2</sup> في الأيام 1 و2 و3 و4 و5 من دورة العلاج ببورﭬيكس.</p><p>كيفية تناول دواء بورﭬيكس</p><p dir="RTL">يُتناول هذا الدواء عن طريق الحقن الوريدي أو بالحقن تحت الجلد. يُعطى بورﭬيكس بواسطة مقدمي الرعاية الصحية المختصين ذوي الخبرة في إعطاء الأدوية المسممة للخلايا.</p><p dir="RTL">يتم تذويب بودرة بورﭬيكس قبل إعطاء الدواء. سيتولى مقدم الرعاية الصحية المختص مسؤولية ذلك. يتم بعد ذلك حقن المحلول الناتج إما عن طريق الوريد أو تحت الجلد. تتم عملية الحقن بشكل سريع حيث تستغرق من 3 إلى 5 ثوانٍ. تتم عملية الحقن تحت الجلد إما في الأفخاذ أو البطن.</p><p>إذا تناولت جرعة أكثر من الموصى بها من دواء بورﭬيكس</p><p dir="RTL">سيُعطى هذا الدواء لك بواسطة الطبيب أو الممرض لذلك فمن المستبعد إعطائك جرعة زائدة. في الحالة مستبعدة الحدوث وهي أخذك لجرعة زائدة، سيقوم طبيبك بوضعك تحت الملاحظة لمعرفة الآثار الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الآثار الجانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى. قد تكون بعض من هذه الآثار الجانبية خطيرة.</p><p dir="RTL">إذا كنت تتناول بورﭬيكس للعلاج من الورم النقوي المتعدد أو سرطان الغدد الليمفاوية، أخبر طبيبك على الفور إذا لاحظت أيًا من الأعراض التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلص العضلات، ضعف في العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطراب أو فقدان البصر أو الاضطرابات النفسية أو صرع أو صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس أو انتفاخ القدمين أو تغير في معدل نبضات القلب أو ارتفاع في ضغط الدم أو التعب أو الإغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال وصعوبة التنفس أو ضيق الصدر.</p><p dir="RTL">من الشائع جدًا أن يتسبب بورﭬيكس في انخفاض كرات الدم البيضاء والحمراء والصفائح الدموية. ومن ثم، سيتعيّن عليك إجراء اختبارات فحص الدم بشكل منتظم قبل وأثناء تناولك دواء بورﭬيكس، للتحقق من عدد خلايا الدم بانتظام. ربما تتعرض لنقصان عدد:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصفائح الدموية والتي قد تجعلك أكثر عرضة للكدمات أو النزيف بدون سبب واضح (مثل حدوث نزيف في الأمعاء أو المعدة أو الفم واللثة أو نزيف في المخ أو في الكبد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كرات الدم الحمراء والتي يمكن لها إحداث فقر الدم المصاحب لأعراض مثل التعب والشحوب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كرات الدم البيضاء والتي قد تجعلك أكثر عرضة للعدوى أو أعراض مشابهة للإنفلونزا.</p><p dir="RTL">وفي حال تناولك لبورﭬيكس لعلاج الورم النقوي المتعدد، قد تظهر عليك الآثار الجانبية الواردة أدناه:</p><p>&nbsp;</p><p>الآثار الجانبية الشائعة جدًا (قد تصيب أكثر من 1 من بين 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية أو فقدان الحس أو التنميل أو الشعور بحرقة في الجلد أو ألم في اليدين أو القدمين نتيجة لحدوث تلف بالأعصاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد كرات الدم الحمراء أو البيضاء (أنظر أعلاه)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب (الغثيان) أو القيئ أو فقدان الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امساك قد يكون مصاحبًا بانتفاخ أو لا (قد يكون حاد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاسهال: يتوجب عليك شرب كمية أكبر من كمية المياه المعتادة في حالة حدوث الاسهال. قد يُعطيك الطبيب دواء آخر لسيطرة على الاسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإرهاق أو الضعف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات أو العظام</p><p>الآثار الجانبية الشائعة (تصيب أكثر من1 من بين 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم والهبوط المفاجئ لضغط الدم عند الوقوف مما قد يؤدي إلى الإغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف وظائف الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور العام بالتعب أو الألم أو الدوار أو الشعور بالدوخة أو الشعور بالضعف أو فقدان الوعي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى بما في ذلك الالتهاب الرئوي وعدوى الجهاز التنفسي والتهاب الشعب الهوائية والعدوى الفطرية والسُعال مع البلغم وأعراض مشابهة للإنفلونزا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحزام الناري (حول العينين أو منتشر في جميع أنحاء الجسم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في الصدر أو ضيق في التنفس عند بذل مجهود بدني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنواع مختلفة من الطفح الجلدي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة في الجلد أو وجود كُتلًا فوق الجلد أو جفاف الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه أو انفجار الشعيرات الدموية الصغيرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة في المعدة أو انتفاخ أو تَجَشُّؤ أو غازات في البطن أو ألم في المعدة أو نزيف من الأمعاء أو المعدة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير وظائف الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم أو الشفاه أو جفاف الفم أو قرحة بالفم أو ألم في الحلق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فُقدان الوزن وفُقدان حاسة التذوق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات في العضلات، تشنجات في العضلات، ضعف في العضلات، ألم في الأطراف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الرؤية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى تصيب الطبقة الخارجية للعين والسطح الداخلي للجفون (التهاب ملتحمة العين).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة أو مشاكل في النوم أو التعرق أو القلق أو تغيرات في الحالة المزاجية أو الإصابة بالإحباط أو الاضطراب أو التهيج العصبي أو تغيير في الحالة العقلية أو التوهان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الجسم، ليشمل حول العينين وأجزاء أخرى من الجسم.</p><p>الآثار الجانبية غير الشائعة (قد تصيب 1 من بين 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة القلبية أو النوبة القلبية أو ألم في الصدر أو الشعور بعدم ارتياح في الصدر أو زيادة أو انخفاض معدل ضربات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد وتجلط الدم في الأوردة والرئتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل تخثر الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور في الدورة الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب تجويف القلب أو تراكم سائل حول القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الأمراض بما في ذلك عدوى المسالك البولية والأنفلونزا وفيروس الهربس والتهاب الأذن والتهاب الهلل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البراز الدموي أو النزيف من الأغشية المخاطية مثل الفم أو المهبل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأوعية الدماغية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شلل أو نوبات صرع أو السقوط أو اختلال في الحركة أو وجود شعور غير طبيعي أو تغير في الحواس (الاحساس أو السمع أو التذوق أو الشم) اضطراب في الانتباه أو الارتجاف أو الارتعاش</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات المفاصل بما في ذلك التهابات مفاصل أصابع اليد والقدم والفك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات التي تؤثر على الرئة مما يمنع من استنشاق الاكسجين بشكل جيد. وتشمل هذه الاضطرابات صعوبة التنفس أو ضيق التنفس أو ضيق التنفس دون بذل جهد أو التنفس الضحل أو صعوبة أو توقف التنفس أو الأزيز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفواق أو اضطرابات النطق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة البول أو انخفاضه (بسبب تلف الكلى)، أو التبول المؤلم للبول أو وجود دم أو بروتينات في البول أو احتباس السوائل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير مستوى الوعي أو التشوش العقلي أو ضعف الذاكرة أو فقدانها</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية المفرطة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع أو ضعف السمع أو وجود طنين في الأذن والشعور بألم في الأذن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير الهرمونات الذي قد يؤثر على امتصاص الماء والملح</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على إفراز الأنسولين أو مقاومة مستويات الأنسولين الطبيعية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج العيون أو التهابها أو العيون المبللة بشكل مفرط أو ألم العيون أو جفافها أو تورم في الجفن (البردة) أو احمرار العين وانتفاخها أو وجود إفرازات من العينين أو الرؤية غير الطبيعية أو نزف العين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم العقد اللمفية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب المفاصل أو العضلات أو الشعور بالثقل أو جود ألم في الأربية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر أو وجود ملمس غير طبيعي للشعر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو ألم في مكان الحقن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الفم أو التهابه أو وجود قرح بالفم والمريء والمعدة والأمعاء والتي تقترن في بعض الأحيان بوجود ألم أو نزيف أو ضعف حركة الأمعاء (بما في ذلك انسداد الامعاء)</p><p dir="RTL">الشعور بعد الارتياح في البطن أو المريء أو وجود صعوبة في البلع أو القيء الدموي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى البكتيرية والفيروسية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الأسنان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس وانسداد قناة الصفراء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الجهاز التناسلي أو وجود مشكلة في الانتصاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العطش</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات التي تتعلق بموضع الحقن أو جهاز الحقن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات والاضطرابات الجلدية (والتي قد تكون بالغة أو مهددة للحياة) أو القرح الجلدية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كدمات إصابات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو نزيف في الأوعية الدموية التي يمكن أن تظهر كنقاط حمراء أو أرجوانية صغيرة (عادة على الساقين) وقد تكون بقع كبيرة تشبه الكدمات تحت الجلد أو الأنسجة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كيسات حميدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة دماغية شديدة الانعكاس بما في ذلك وجود نوبات أو ارتفاع ضغط الدم أو الصداع أو التعب أو التشوش أو العمى أو مشاكل أخرى في الرؤية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصاة صفراوية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فتاق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الإصابة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هشاشة أو ضعف بالأظافر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رواسب البروتين غير الطبيعية بالأعضاء الحيوية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غيبوبة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قَرْحاتُ عُسْرِ الهَضْم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الأعضاء المتعدد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوفاة</p><p dir="RTL">حال تناول بورﭬيكس مع تناول الأدوية الأخرى المعالجة لسرطان الغدة الليمفاوية، تظهر عليه الآثار الجانبية الموضحة أدناه:</p><p dir="RTL"><strong>الآثار الجانبية الشائعة للغاية (قد تصيب أكثر من 1 بين 10 أشخاص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية أو اخدرار أو ذخر أو حرقة بالجلد أو الشعور بالألم في اليد والقدم نتيجة لحدوث تلف بالأعصاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان والقيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة بالفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات أو العظام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر أو وجود ملمس غير طبيعي للشعر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإرهاق أو الضعف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL"><strong>الآثار الجانبية الشائعة (تصيب 1 من بين 10 أشخاص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحزام الناري (الذي يتواجد أو ينتشر حول العينين أو في جميع أنحاء الجسم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بفيروس هربس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى البكتيرية والفيروسية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات التنفسية أو التهاب الشعب الهوائية أو السعال المصحوب بالبلغم والآثار الشبيهة بالأنفلونزا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التلوثات الفطرية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية (رد الفعل التحسسي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على إفراز الإنسولين أو مقاومة مستويات الإنسولين الطبيعية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السائل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات أو مشكلات النوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير مستوى الوعي، التشوش</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور الدوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ضربات القلب وارتفاع ضغط الدم والتعرق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية غير الطبيعية أو تشوش الرؤية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة القلبية أو النوبة القلبية أو ألم في الصدر أو الشعور بعدم ارتياح في الصدر أو زيادة أو انخفاض معدل ضربات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهبوط المفاجئ في ضغط الدم عند الوقوف مما يؤدي إلى الإغماء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصر النفس بالتمرينات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفواق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين الأذن أو ألم بالأذن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الأمعاء والمعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة الفؤاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمعدة أو الانتفاخات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والامعاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرح الفم أو الشفاه أو ألم بالحلق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير وظائف الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج عضلي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الجهاز البولي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الأطراف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الجسم ليشمل العينين وأجزاء أخرى من الجسم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو ألم في مكان الحقن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإجهاد العام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تصيب 1 من بين 100 شخص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي وخيم (رد فعل تحسسي) وقد يشتمل على علامات صعوبة التنفس أو ألم في الصدر أو ضيق الصدر و/أو الشعور بالدوار/الإغماء أو حكة شديدة في الجلد أو كتل مرتفعة فوق الجلد و/أو تورم في الوجه والشفاه واللسان و/أو الحلق، مما يسبب صعوبة في البلع والإغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الحركة أو الشلل أو نفضان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع أو الصمم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات التي تؤثر على الرئة مما يمنع من استنشاق الاكسجين بشكل جيد. وتشمل هذه الاضطرابات صعوبة التنفس أو ضيق التنفس أو ضيق التنفس دون بذل جهد أو التنفس الضحل أو صعوبة في التنفس أو توقفه أو الأزيز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية بالرئتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلون العينين والجلد باللون الأصفر (اليرقان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم جفن العين (البردة)، جفن عين محمر ومنتفخ</p><p dir="RTL"><strong>الآثار الجانبية النادرة (قد تصيب1 من بين 1000 شخص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدم في الأوعية الدموية الصغيرة (اعتلال الأوعية الدموية الخُثاري)</p><p dir="RTL">يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء عن طريق الإبلاغ عن الآثار الجانبية التي تواجهك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيداً عن متناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على الأنبولة الدواء وعلى العبوة بعد كلمة &quot;انتهاء&quot;. يجب عدم تخزين الأنبولة في درجة حرارة أعلى من 25 درجة مئوية قم بحفظ أمبولة الدواء بعلبتها الخارجية بغرض حمايتها من الضوء.</p><p dir="RTL">يجب أن يستخدم المحلول المجهز على الفور بعد إعداده. خال عدم استخدام المحلول المجهز</p><p dir="RTL">على الفور، فعليه تقع مسؤولية عدد مرات التخزين وحالة الدواء قبل استخدامه على عاتق المُستخدم. على الرغم من ذلك، يعد المحلول المجهز ثابت لمدة ثمانية ساعات على درجة حرارة 25 مئوية ومخزنة بأنبولة أصلية و/أو محقنة، بإجمالي ساعات تخزين لكل دواء مجهز لا تتجاوز ثمانية ساعات قبل تناولها.</p><p dir="RTL">يستخدم بورﭬيكس لمرة واحدة فقط. يجب التخلص من أي منتج غير مستخدم أو نفايات المواد وفقًا للمتطلبات المحلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة بالدواء هي بورتيزوميب. حيث تحتوي كل أمبولة على 3.5 ملغم من بورتيزوميب (باعتباره مانيتول استر البورونيت)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باقي المكونات: مانيتول (E421)، تيرت بيوتايل الكحول ونيتروجين.</p><p dir="RTL">الإذابة للوريد:</p><p dir="RTL">بعد الإذابة، 1مل من محلول الحقن الوريدي والمحتوي على 1 ملغم منبورتيزوميب.</p><p dir="RTL">الإذابة لتحت الجلد:</p><p dir="RTL">بعد الإذابة، 1مل من محلول الحقن تحت الجلد والمحتوي على 2.5 ملغم منبورتيزوميب.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تعد بودرة البورﭬيكس لمحلول الحقن هي بودرة أو كتلة بيضاء أو ذات لون ابيض مائل إلى الصفرة.</p><p dir="RTL">وتحوي كل علبة من البورﭬيكس ذات 3.5 ملغم من بودرة المحلول للأغراض الحقن على أنبولة &nbsp;زجاجية 10 مل &nbsp;مع سدادة مطاطية 13 ملم وغطاء بلاستيكي من الألومنيوم مقاس 13 ملم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p dir="RTL">&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المُصنّعة:</strong></p><p dir="RTL">شركة كيلو الدوائية المحدودة - الصين لصالح إم إس فارما - السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Nov-19
SPM190547

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BORVIX 3.5 mg powder for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 3.5 mg bortezomib (as a mannitol boronic ester).
After reconstitution, 1 ml of solution for subcutaneous injection contains 2.5 mg bortezomib.
After reconstitution, 1 ml of solution for intravenous injection contains 1 mg bortezomib.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection.
White to off-white cake or powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BORVIX as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.</p><p>BORVIX in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.</p><p>BORVIX in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.</p><p>BORVIX in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BORVIX treatment must be initiated under supervision of a physician experienced in the treatment of cancer patients, however BORVIX may be administered by a healthcare professional experienced in use of chemotherapeutic agents. BORVIX must be reconstituted by a healthcare professional (see section 6.6).</p><p><u>Posology for treatment of progressive multiple myeloma (patients who have received at least one prior therapy)</u></p><p><em>Monotherapy</em></p><p>BORVIX 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m<sup>2</sup>&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21-day treatment cycle. This 3-week period is considered a treatment cycle. It is recommended that patients receive 2 cycles of BORVIX following a confirmation of a complete response. It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles of BORVIX therapy. At least 72 hours should elapse between consecutive doses of BORVIX.</p><p><em>Dose adjustments during treatment and re-initiation of treatment for monotherapy</em></p><p>BORVIX treatment must be withheld at the onset of any Grade 3 non-haematological or any Grade 4 haematological toxicities, excluding neuropathy as discussed below (see also section 4.4). Once the symptoms of the toxicity have resolved, BORVIX treatment may be re-initiated at a 25% reduced dose (1.3 mg/m<sup>2</sup>&nbsp;reduced to 1.0 mg/m<sup>2</sup>; 1.0 mg/m<sup>2</sup>&nbsp;reduced to 0.7 mg/m<sup>2</sup>). If the toxicity is not resolved or if it recurs at the lowest dose, discontinuation of BORVIX must be considered unless the benefit of treatment clearly outweighs the risk.</p><p><em>Neuropathic pain and/or peripheral neuropathy</em></p><p>Patients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in Table 1 (see section 4.4). Patients with pre-existing severe neuropathy may be treated with BORVIX only after careful risk/benefit assessment.</p><p><em>Table 1: Recommended* posology modifications for bortezomib-related neuropathy</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Severity of neuropathy</strong></p></td><td style="vertical-align:top"><p><strong>Posology modification</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 1 (asymptomatic; loss of deep tendon reflexes or paresthesia) with no pain or loss of function</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Grade 1 with pain or Grade 2 (moderate symptoms; limiting instrumental Activities of Daily Living (ADL)**)</p></td><td style="vertical-align:top"><p>Reduce BORVIX to 1.0 mg/m<sup>2</sup></p><p>or</p><p>Change BORVIX treatment schedule to 1.3 mg/m<sup>2</sup>&nbsp;once per week</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2 with pain or Grade 3 (severe symptoms; limiting self care ADL***)</p></td><td style="vertical-align:top"><p>Withhold BORVIX treatment until symptoms of toxicity have resolved. When toxicity resolves re-initiate BORVIX treatment and reduce dose to 0.7 mg/m<sup>2</sup>&nbsp;once per week.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4 (life-threatening consequences; urgent intervention indicated) and/or severe autonomic neuropathy</p></td><td style="vertical-align:top"><p>Discontinue BORVIX</p></td></tr></tbody></table><p>* Based on posology modifications in Phase II and III multiple myeloma studies and post-marketing experience. Grading based on NCI Common Toxicity Criteria CTCAE v 4.0.</p><p>**&nbsp;<em>Instrumental ADL</em>: refers to preparing meals, shopping for groceries or clothes, using telephone, managing money, etc;</p><p>***&nbsp;<em>Self care ADL</em>: refers to bathing, dressing and undressing, feeding self, using the toilet, taking medicinal products, and not bedridden.</p><p><em>Combination therapy with pegylated liposomal doxorubicin</em></p><p>BORVIX 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m<sup>2</sup>&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21-day treatment cycle. This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of BORVIX.</p><p>Pegylated liposomal doxorubicin is administered at 30 mg/m<sup>2</sup>&nbsp;on day 4 of the BORVIX treatment cycle as a 1 hour intravenous infusion administered after the BORVIX injection.</p><p>Up to 8 cycles of this combination therapy can be administered as long as patients have not progressed and tolerate treatment. Patients achieving a complete response can continue treatment for at least 2 cycles after the first evidence of complete response, even if this requires treatment for more than 8 cycles. Patients whose levels of paraprotein continue to decrease after 8 cycles can also continue for as long as treatment is tolerated and they continue to respond.</p><p>For additional information concerning pegylated liposomal doxorubicin, see the corresponding Summary of Product Characteristics.</p><p><em>Combination with dexamethasone</em></p><p>BORVIX 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m<sup>2</sup>&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21 day treatment cycle. This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of BORVIX.</p><p>Dexamethasone is administered orally at 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12 of the BORVIX treatment cycle.</p><p>Patients achieving a response or a stable disease after 4 cycles of this combination therapy can continue to receive the same combination for a maximum of 4 additional cycles.</p><p>For additional information concerning dexamethasone, see the corresponding Summary of Product Characteristics.</p><p><em>Dose adjustments for combination therapy for patients with progressive multiple myeloma</em></p><p>For BORVIX dosage adjustments for combination therapy follow dose modification guidelines described under monotherapy above.</p><p><u>Posology for previously untreated multiple myeloma patients not eligible for haematopoietic stem cell transplantation</u></p><p><em>Combination therapy with melphalan and prednisone</em></p><p>BORVIX 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection in combination with oral melphalan and oral prednisone as shown in Table 2. A 6-week period is considered a treatment cycle. In Cycles 1-4, BORVIX is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32. In Cycles 5-9, BORVIX is administered once weekly on days 1, 8, 22 and 29. At least 72 hours should elapse between consecutive doses of BORVIX.</p><p>Melphalan and prednisone should both be given orally on days 1, 2, 3 and 4 of the first week of each BORVIX treatment cycle.</p><p>Nine treatment cycles of this combination therapy are administered.</p><p><em>Table 2: Recommended posology for BORVIX in combination with melphalan and prednisone</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="14" style="vertical-align:top"><p><strong>Twice weekly BORVIX (cycles 1-4)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>2</strong></p></td><td style="vertical-align:top"><p><strong>3</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>4</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p><strong>6</strong></p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vc (1.3 mg/m<sup>2)</sup></p></td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Day 4</p></td><td style="vertical-align:top"><p>Day 8</p></td><td style="vertical-align:top"><p>Day 11</p></td><td style="vertical-align:top"><p>rest period</p></td><td style="vertical-align:top"><p>Day 22</p></td><td style="vertical-align:top"><p>Day 25</p></td><td style="vertical-align:top"><p>Day 29</p></td><td style="vertical-align:top"><p>Day 32</p></td><td style="vertical-align:top"><p>rest period</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>M (9 mg/m<sup>2</sup>)</p><p>P (60 mg/m<sup>2)</sup></p></td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Day 2</p></td><td style="vertical-align:top"><p>Day 3</p></td><td style="vertical-align:top"><p>Day 4</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>rest period</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>rest period</p></td><td>&nbsp;</td></tr><tr><td colspan="14" style="vertical-align:top"><p><strong>Once weekly BORVIX (cycles 5-9)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>2</strong></p></td><td style="vertical-align:top"><p><strong>3</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>4</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p><strong>6</strong></p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vc (1.3 mg/m<sup>2)</sup></p></td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td colspan="2" style="vertical-align:top"><p>Day 8</p></td><td style="vertical-align:top"><p>rest period</p></td><td colspan="2" style="vertical-align:top"><p>Day 22</p></td><td colspan="2" style="vertical-align:top"><p>Day 29</p></td><td style="vertical-align:top"><p>rest period</p></td><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>M (9 mg/m<sup>2</sup>)</p><p>P (60 mg/m<sup>2)</sup></p></td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Day 2</p></td><td style="vertical-align:top"><p>Day 3</p></td><td style="vertical-align:top"><p>Day 4</p></td><td colspan="2" style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>rest period</p></td><td colspan="2" style="vertical-align:top"><p>--</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>rest period</p></td><td>&nbsp;</td></tr></tbody></table><p>Vc=BORVIX; M=melphalan, P=prednisone</p><p><em>Dose adjustments during treatment and re-initiation of treatment for combination therapy with melphalan and prednisone</em></p><p>Prior to initiating a new cycle of therapy:</p><p>&bull; Platelet counts should be &ge; 70 x 10<sup>9</sup>/l and the absolute neutrophils count should be &ge; 1.0 x 10<sup>9</sup>/l</p><p>&bull; Non-haematological toxicities should have resolved to Grade 1 or baseline</p><p><em>Table 3: Posology modifications during subsequent cycles of BORVIX therapy in combination with melphalan and prednisone</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Posology modification or delay</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haematological toxicity during a cycle</em></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>&bull; If prolonged Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle</p></td><td style="vertical-align:top"><p>Consider reduction of the melphalan dose by 25% in the next cycle.</p></td></tr><tr><td style="vertical-align:top"><p>&bull; If platelet counts &le; 30 x 10<sup>9</sup>/l or ANC &le; 0.75 x 10<sup>9</sup>/l on a BORVIX dosing day (other than day 1)</p></td><td style="vertical-align:top"><p>BORVIX therapy should be withheld</p></td></tr><tr><td style="vertical-align:top"><p>&bull; If several BORVIX doses in a cycle are withheld (&ge; 3 doses during twice weekly administration or &ge; 2 doses during weekly administration)</p></td><td style="vertical-align:top"><p>BORVIX dose should be reduced by 1 dose level (from 1.3 mg/m<sup>2</sup>&nbsp;to 1 mg/m<sup>2</sup>, or from 1 mg/m<sup>2</sup>&nbsp;to 0.7 mg/m<sup>2</sup>)</p></td></tr><tr><td style="vertical-align:top"><p><em>Grade &ge; 3 non-haematological toxicities</em></p></td><td style="vertical-align:top"><p>BORVIX therapy should be withheld until symptoms of the toxicity have resolved to Grade 1 or baseline. Then, BORVIX may be reinitiated with one dose level reduction (from 1.3 mg/m<sup>2</sup>&nbsp;to 1 mg/m<sup>2</sup>, or from 1 mg/m<sup>2</sup>&nbsp;to 0.7 mg/m<sup>2</sup>). For BORVIX-related neuropathic pain and/or peripheral neuropathy, hold and/or modify BORVIX as outlined in Table 1.</p></td></tr></tbody></table><p>For additional information concerning melphalan and prednisone, see the corresponding Summary of Product Characteristics.</p><p><u>Posology for previously untreated multiple myeloma patients eligible for haematopoietic stem cell transplantation (induction therapy)</u></p><p><em>Combination therapy with dexamethasone</em></p><p>BORVIX 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m<sup>2</sup>&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21-day treatment cycle. This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of BORVIX.</p><p>Dexamethasone is administered orally at 40 mg on days 1, 2, 3, 4, 8, 9, 10 and 11 of the BORVIX treatment cycle.</p><p>Four treatment cycles of this combination therapy are administered.</p><p><em>Combination therapy with dexamethasone and thalidomide</em></p><p>BORVIX 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m<sup>2</sup>&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 28-day treatment cycle. This 4-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of BORVIX.</p><p>Dexamethasone is administered orally at 40 mg on days 1, 2, 3, 4, 8, 9, 10 and 11 of the BORVIX treatment cycle.</p><p>Thalidomide is administered orally at 50 mg daily on days 1-14 and if tolerated the dose is increased to 100 mg on days 15-28, and thereafter may be further increased to 200 mg daily from cycle 2 (see Table 4).</p><p>Four treatment cycles of this combination are administered. It is recommended that patients with at least partial response receive 2 additional cycles.</p><p><em>Table 4: Posology for BORVIX combination therapy for patients with previously untreated multiple myeloma eligible for haematopoietic stem cell transplantation</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="4" style="vertical-align:top"><p><strong>Vc+ Dx</strong></p></td><td colspan="7" style="vertical-align:top"><p><strong>Cycles 1 to 4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>3</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vc (1.3 mg/m<sup>2</sup>)</p></td><td colspan="2" style="vertical-align:top"><p>Day 1, 4</p></td><td colspan="2" style="vertical-align:top"><p>Day 8, 11</p></td><td colspan="2" style="vertical-align:top"><p>Rest Period</p></td></tr><tr><td style="vertical-align:top"><p>Dx 40 mg</p></td><td colspan="2" style="vertical-align:top"><p>Day 1, 2, 3, 4</p></td><td colspan="2" style="vertical-align:top"><p>Day 8, 9, 10, 11</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p><strong>Vc+Dx+T</strong></p></td><td colspan="7" style="vertical-align:top"><p><strong>Cycle 1</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>2</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>3</strong></p></td><td style="vertical-align:top"><p><strong>4</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vc (1.3 mg/m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Day 1, 4</p></td><td colspan="2" style="vertical-align:top"><p>Day 8, 11</p></td><td colspan="2" style="vertical-align:top"><p>Rest Period</p></td><td style="vertical-align:top"><p>Rest Period</p></td></tr><tr><td style="vertical-align:top"><p>T 50 mg</p></td><td style="vertical-align:top"><p>Daily</p></td><td colspan="2" style="vertical-align:top"><p>Daily</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>T 100 mg<sup>a</sup></p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>Daily</p></td><td style="vertical-align:top"><p>Daily</p></td></tr><tr><td style="vertical-align:top"><p>Dx 40 mg</p></td><td style="vertical-align:top"><p>Day 1, 2, 3, 4</p></td><td colspan="2" style="vertical-align:top"><p>Day 8, 9, 10, 11</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Cycles 2 to 4<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Vc (1.3 mg/m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Day 1, 4</p></td><td colspan="2" style="vertical-align:top"><p>Day 8, 11</p></td><td colspan="2" style="vertical-align:top"><p>Rest Period</p></td><td style="vertical-align:top"><p>Rest Period</p></td></tr><tr><td style="vertical-align:top"><p>T 200 mg<sup>a</sup></p></td><td style="vertical-align:top"><p>Daily</p></td><td colspan="2" style="vertical-align:top"><p>Daily</p></td><td colspan="2" style="vertical-align:top"><p>Daily</p></td><td style="vertical-align:top"><p>Daily</p></td></tr><tr><td style="vertical-align:top"><p>Dx 40 mg</p></td><td style="vertical-align:top"><p>Day 1, 2, 3, 4</p></td><td colspan="2" style="vertical-align:top"><p>Day 8, 9, 10, 11</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Vc=BORVIX; Dx=dexamethasone; T=thalidomide</p><p><sup>a</sup>&nbsp;Thalidomide dose is increased to 100 mg from week 3 of Cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2 onwards if 100 mg is tolerated.</p><p><sup>b</sup>&nbsp;Up to 6 cycles may be given to patients who achieve at least a partial response after 4 cycles</p><p><em>Dosage adjustments for transplant eligible patients</em></p><p>For BORVIX dosage adjustments, dose modification guidelines described for monotherapy should be followed.</p><p>In addition, when BORVIX is given in combination with other chemotherapeutic medicinal products, appropriate dose reductions for these products should be considered in the event of toxicities according to the recommendations in the Summary of Product Characteristics.</p><p><u>Posology for patients with previously untreated mantle cell lymphoma (MCL)</u></p><p><em>Combination therapy with rituximab, cyclophosphamide, doxorubicin and prednisone (VcR-CAP)</em></p><p>BORVIX 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m<sup>2</sup>&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11, followed by a 10-day rest period on days 12-21. This 3-week period is considered a treatment cycle. Six BORVIX cycles are recommended, although for patients with a response first documented at cycle 6, two additional BORVIX cycles may be given. At least 72 hours should elapse between consecutive doses of BORVIX.</p><p>The following medicinal products are administered on day 1 of each BORVIX 3 week treatment cycle as intravenous infusions: rituximab at 375 mg/m<sup>2</sup>, cyclophosphamide at 750 mg/m<sup>2</sup>&nbsp;and doxorubicin at 50 mg/m<sup>2</sup>.</p><p>Prednisone is administered orally at 100 mg/m<sup>2</sup>&nbsp;on days 1, 2, 3, 4 and 5 of each BORVIX treatment cycle.</p><p><em>Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma</em></p><p>Prior to initiating a new cycle of therapy:</p><p>&bull; Platelet counts should be &ge; 100,000 cells/&mu;L and the absolute neutrophils count (ANC) should be &ge; 1,500 cells/&mu;L</p><p>&bull; Platelet counts should be &ge; 75,000 cells/&mu;L in patients with bone marrow infiltration or splenic sequestration</p><p>&bull; Haemoglobin &ge; 8 g/dL</p><p>&bull; Non-haematological toxicities should have resolved to Grade 1 or baseline.</p><p>BORVIX treatment must be withheld at the onset of any &ge; Grade 3 BORVIX-related non-haematological toxicities (excluding neuropathy) or &ge; Grade 3 haematological toxicities (see also section 4.4). For dose adjustments, see Table 5 below.</p><p>Granulocyte colony stimulating factors may be administered for haematologic toxicity according to local standard practice. Prophylactic use of granulocyte colony stimulating factors should be considered in case of repeated delays in cycle administration. Platelet transfusion for the treatment of thrombocytopenia should be considered when clinically appropriate.</p><p><em>Table 5: Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Posology modification or delay</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Haematological toxicity</em></p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp; &ge; Grade 3 neutropenia with fever, Grade 4 neutropenia lasting more than 7 days, a platelet count &lt; 10,000 cells/&mu;L</p></td><td style="vertical-align:top"><p>BORVIX therapy should be withheld for up to 2 weeks until the patient has an ANC &ge; 750 cells/&mu;L and a platelet count &ge; 25,000 cells/&mu;L.</p><p>&bull; If, after BORVIX has been held, the toxicity does not resolve, as defined above, then BORVIX must be discontinued.</p><p>&bull; If toxicity resolves i.e. patient has an ANC &ge; 750 cells/&mu;L and a platelet count &ge; 25,000 cells/&mu;L, BORVIX may be reinitiated at a dose reduced by one dose level (from 1.3 mg/m<sup>2</sup>&nbsp;to 1 mg/m<sup>2</sup>, or from 1 mg/m<sup>2</sup>&nbsp;to 0.7 mg/m<sup>2</sup>).</p></td></tr><tr><td style="vertical-align:top"><p>&bull; If platelet counts &lt; 25,000 cells/&mu;L. or ANC &lt; 750 cells/&mu;L on a BORVIX dosing day (other than Day 1 of each cycle)</p></td><td style="vertical-align:top"><p>BORVIX therapy should be withheld</p></td></tr><tr><td style="vertical-align:top"><p><em>Grade &ge; 3 non-haematological toxicities considered to be related to BORVIX</em></p></td><td style="vertical-align:top"><p>BORVIX therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better. Then, BORVIX may be reinitiated at a dose reduced by one dose level (from 1.3 mg/m<sup>2</sup>&nbsp;to 1 mg/m<sup>2</sup>, or from 1 mg/m<sup>2</sup>&nbsp;to 0.7 mg/m<sup>2</sup>). For BORVIX-related neuropathic pain and/or peripheral neuropathy, hold and/or modify BORVIX as outlined in Table 1.</p></td></tr></tbody></table><p>In addition, when BORVIX is given in combination with other chemotherapeutic medicinal products, appropriate dose reductions for these medicinal products should be considered in the event of toxicities, according to the recommendations in the respective Summary of Product Characteristics.</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>There is no evidence to suggest that dose adjustments are necessary in patients over 65 years of age with multiple myeloma or with mantle cell lymphoma.</p><p>There are no studies on the use of BORVIX in elderly patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Therefore no dose recommendations can be made in this population.</p><p>In a study in previously untreated mantle cell lymphoma patients, 42.9% and 10.4% of patients exposed to BORVIX were in the range 65-74 years and &ge; 75 years of age, respectively. In patients aged &ge; 75 years, both regimens, VcR-CAP as well as R-CHOP, were less tolerated (see section 4.8).</p><p><em>Hepatic impairment</em></p><p>Patients with mild hepatic impairment do not require a dose adjustment and should be treated per the recommended dose. Patients with moderate or severe hepatic impairment should be started on BORVIX at a reduced dose of 0.7 mg/m<sup>2</sup>&nbsp;per injection during the first treatment cycle, and a subsequent dose escalation to 1.0 mg/m<sup>2</sup>&nbsp;or further dose reduction to 0.5 mg/m<sup>2</sup>&nbsp;may be considered based on patient tolerability (see Table 6 and sections 4.4 and 5.2).</p><p><em>Table 6: Recommended starting dose modification for BORVIX in patients with hepatic impairment</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Grade of hepatic impairment*</strong></p></td><td style="vertical-align:top"><p><strong>Bilirubin level</strong></p></td><td style="vertical-align:top"><p><strong>SGOT (AST) levels</strong></p></td><td style="vertical-align:top"><p><strong>Modification of starting dose</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>&le; 1.0 x ULN</p></td><td style="vertical-align:top"><p>&gt; ULN</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1.0 x &minus;1.5 x ULN</p></td><td style="vertical-align:top"><p>Any</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>&gt; 1.5 x &minus;3 x ULN</p></td><td style="vertical-align:top"><p>Any</p></td><td rowspan="2" style="vertical-align:top"><p>Reduce BORVIX to 0.7 mg/m<sup>2</sup>&nbsp;in the first treatment cycle. Consider dose escalation to 1.0 mg/m<sup>2</sup>&nbsp;or further dose reduction to 0.5 mg/m<sup>2</sup>&nbsp;in subsequent cycles based on patient tolerability.</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>&gt; 3 x ULN</p></td><td style="vertical-align:top"><p>Any</p></td></tr></tbody></table><p>Abbreviations: SGOT=serum glutamic oxaloacetic transaminase;</p><p>AST=aspartate aminotransferase; ULN=upper limit of the normal range.</p><p>* Based on NCI Organ Dysfunction Working Group classification for categorising hepatic impairment (mild, moderate, severe).</p><p><em>Renal impairment</em></p><p>The pharmacokinetics of bortezomib are not influenced in patients with mild to moderate renal impairment (Creatinine Clearance [CrCL] &gt; 20 ml/min/1.73 m<sup>2</sup>); therefore, dose adjustments are not necessary for these patients. It is unknown if the pharmacokinetics of bortezomib are influenced in patients with severe renal impairment not undergoing dialysis (CrCL &lt; 20 ml/min/1.73 m<sup>2</sup>). Since dialysis may reduce bortezomib concentrations, BORVIX should be administered after the dialysis procedure (see section 5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of BORVIX in children below 18 years of age have not been established (see sections 5.1 and 5.2). Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p><u>Method of administration</u></p><p>BORVIX 3.5 mg powder for solution for injection is available for intravenous or subcutaneous administration.</p><p>BORVIX 1 mg powder for solution for injection is available for intravenous administration only.</p><p>BORVIX should not be given by other routes. Intrathecal administration has resulted in death.</p><p><em>Intravenous injection</em></p><p>BORVIX 3.5 mg reconstituted solution is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with sodium chloride 9 mg/ml (0.9%) solution for injection. At least 72 hours should elapse between consecutive doses of BORVIX.</p><p><em>Subcutaneous injection</em></p><p>BORVIX 3.5 mg reconstituted solution is administered subcutaneously through the thighs (right or left) or abdomen (right or left). The solution should be injected subcutaneously, at a 45-90&deg; angle. Injection sites should be rotated for successive injections.</p><p>If local injection site reactions occur following BORVIX subcutaneous injection, either a less concentrated BORVIX solution (BORVIX 3.5 mg to be reconstituted to 1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.</p><p>When BORVIX is given in combination with other medicinal products, refer to the Summary of Product Characteristics of these products for instructions for administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to boron or to any of the excipients listed in section 6.1.
Acute diffuse infiltrative pulmonary and pericardial disease.
When BORVIX is given in combination with other medicinal products, refer to their Summaries of Product Characteristics for additional contraindications.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When BORVIX is given in combination with other medicinal products, the Summary of Product Characteristics of these other medicinal products must be consulted prior to initiation of treatment with BORVIX. When thalidomide is used, particular attention to pregnancy testing and prevention requirements is needed (see section 4.6).</p><p><u>Intrathecal administration</u></p><p>There have been fatal cases of inadvertent intrathecal administration of BORVIX. BORVIX 1 mg powder for solution for injection is for intravenous use only, while BORVIX 3.5 mg powder for solution for injection is for intravenous or subcutaneous use. BORVIX should not be administered intrathecally.</p><p><u>Gastrointestinal toxicity</u></p><p>Gastrointestinal toxicity, including nausea, diarrhoea, vomiting and constipation are very common with BORVIX treatment. Cases of ileus have been uncommonly reported (see section 4.8). Therefore, patients who experience constipation should be closely monitored.</p><p><u>Haematological toxicity</u></p><p>BORVIX treatment is very commonly associated with haematological toxicities (thrombocytopenia, neutropenia and anaemia). In studies in patients with relapsed multiple myeloma treated with BORVIX and in patients with previously untreated MCL treated with BORVIX in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP), one of the most common haematologic toxicity was transient thrombocytopenia. Platelets were lowest at Day 11 of each cycle of BORVIX treatment and typically recovered to baseline by the next cycle. There was no evidence of cumulative thrombocytopenia. The mean platelet count nadir measured was approximately 40% of baseline in the single-agent multiple myeloma studies and 50% in the MCL study. In patients with advanced myeloma the severity of thrombocytopenia was related to pre-treatment platelet count: for baseline platelet counts &lt; 75,000/&mu;l, 90% of 21 patients had a count &le; 25,000/&mu;l during the study, including 14% &lt; 10,000/&mu;l; in contrast, with a baseline platelet count &gt; 75,000/&mu;l, only 14% of 309 patients had a count &le; 25,000/&mu;l during the study.</p><p>In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade &ge; 3 thrombocytopenia in the BORVIX treatment group (VcR-CAP) as compared to the non-BORVIX treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]). The two treatment groups were similar with regard to the overall incidence of all-grade bleeding events (6.3% in the VcR-CAP group and 5.0% in the R-CHOP group) as well as Grade 3 and higher bleeding events (VcR-CAP: 4 patients [1.7%]; R-CHOP: 3 patients [1.2%]). In the VcR-CAP group, 22.5% of patients received platelet transfusions compared to 2.9% of patients in the R-CHOP group.</p><p>Gastrointestinal and intracerebral haemorrhage, have been reported in association with BORVIX treatment. Therefore, platelet counts should be monitored prior to each dose of BORVIX. BORVIX therapy should be withheld when the platelet count is &lt; 25,000/&mu;l or, in the case of combination with melphalan and prednisone, when the platelet count is &le; 30,000/&mu;l (see section 4.2). Potential benefit of the treatment should be carefully weighed against the risks, particularly in case of moderate to severe thrombocytopenia and risk factors for bleeding.</p><p>Complete blood counts (CBC) with differential and including platelet counts should be frequently monitored throughout treatment with BORVIX. Platelet transfusion should be considered when clinically appropriate (see section 4.2).</p><p>In patients with MCL, transient neutropenia that was reversible between cycles was observed, with no evidence of cumulative neutropenia. Neutrophils were lowest at Day 11 of each cycle of BORVIX treatment and typically recovered to baseline by the next cycle. In study LYM-3002, colony stimulating factor support was given to 78% of patients in the VcR-CAP arm and 61% of patients in the R-CHOP arm. Since patients with neutropenia are at increased risk of infections, they should be monitored for signs and symptoms of infection and treated promptly. Granulocyte colony stimulating factors may be administered for haematologic toxicity according to local standard practice. Prophylactic use of granulocyte colony stimulating factors should be considered in case of repeated delays in cycle administration (see section 4.2).</p><p><u>Herpes zoster virus reactivation</u></p><p>Antiviral prophylaxis is recommended in patients being treated with BORVIX.</p><p>In the Phase III study in patients with previously untreated multiple myeloma, the overall incidence of herpes zoster reactivation was more common in patients treated with BORVIX+Melphalan+Prednisone compared with Melphalan+Prednisone (14% versus 4% respectively).</p><p>In patients with MCL (study LYM-3002), the incidence of herpes zoster infection was 6.7% in the VcR-CAP arm and 1.2% in the R-CHOP arm (see section 4.8).</p><p><u>Hepatitis B Virus (HBV) reactivation and infection</u></p><p>When rituximab is used in combination with BORVIX, HBV screening must always be performed in patients at risk of infection with HBV before initiation of treatment. Carriers of hepatitis B and patients with a history of hepatitis B must be closely monitored for clinical and laboratory signs of active HBV infection during and following rituximab combination treatment with BORVIX. Antiviral prophylaxis should be considered. Refer to the Summary of Product Characteristics of rituximab for more information.</p><p><u>Progressive multifocal leukoencephalopathy (PML)</u></p><p>Very rare cases with unknown causality of John Cunningham (JC) virus infection, resulting in PML and death, have been reported in patients treated with BORVIX. Patients diagnosed with PML had prior or concurrent immunosuppressive therapy. Most cases of PML were diagnosed within 12 months of their first dose of BORVIX. Patients should be monitored at regular intervals for any new or worsening neurological symptoms or signs that may be suggestive of PML as part of the differential diagnosis of CNS problems. If a diagnosis of PML is suspected, patients should be referred to a specialist in PML and appropriate diagnostic measures for PML should be initiated. Discontinue BORVIX if PML is diagnosed.</p><p><u>Peripheral neuropathy</u></p><p>Treatment with BORVIX is very commonly associated with peripheral neuropathy, which is predominantly sensory. However, cases of severe motor neuropathy with or without sensory peripheral neuropathy have been reported. The incidence of peripheral neuropathy increases early in the treatment and has been observed to peak during cycle 5.</p><p>It is recommended that patients be carefully monitored for symptoms of neuropathy such as a burning sensation, hyperesthesia, hypoesthesia, paraesthesia, discomfort, neuropathic pain or weakness.</p><p>In the Phase III study comparing BORVIX administered intravenously versus subcutaneously, the incidence of Grade &ge; 2 peripheral neuropathy events was 24% for the subcutaneous injection group and 41% for the intravenous injection group (p=0.0124). Grade &ge; 3 peripheral neuropathy occurred in 6% of patients in the subcutaneous treatment group, compared with 16% in the intravenous treatment group (p=0.0264). The incidence of all grade peripheral neuropathy with BORVIX administered intravenously was lower in the historical studies with BORVIX administered intravenously than in study MMY-3021.</p><p>Patients experiencing new or worsening peripheral neuropathy should undergo neurological evaluation and may require a change in the dose, schedule or route of administration to subcutaneous (see section 4.2). Neuropathy has been managed with supportive care and other therapies.</p><p>Early and regular monitoring for symptoms of treatment-emergent neuropathy with neurological evaluation should be considered in patients receiving BORVIX in combination with medicinal products known to be associated with neuropathy (e.g. thalidomide) and appropriate dose reduction or treatment discontinuation should be considered.</p><p>In addition to peripheral neuropathy, there may be a contribution of autonomic neuropathy to some adverse reactions such as postural hypotension and severe constipation with ileus. Information on autonomic neuropathy and its contribution to these undesirable effects is limited.</p><p><u>Seizures</u></p><p>Seizures have been uncommonly reported in patients without previous history of seizures or epilepsy. Special care is required when treating patients with any risk factors for seizures.</p><p><u>Hypotension</u></p><p>BORVIX treatment is commonly associated with orthostatic/postural hypotension. Most adverse reactions are mild to moderate in nature and are observed throughout treatment. Patients who developed orthostatic hypotension on BORVIX (injected intravenously) did not have evidence of orthostatic hypotension prior to treatment with BORVIX. Most patients required treatment for their orthostatic hypotension. A minority of patients with orthostatic hypotension experienced syncopal events. Orthostatic/postural hypotension was not acutely related to bolus infusion of BORVIX. The mechanism of this event is unknown although a component may be due to autonomic neuropathy. Autonomic neuropathy may be related to bortezomib or bortezomib may aggravate an underlying condition such as diabetic or amyloidotic neuropathy. Caution is advised when treating patients with a history of syncope receiving medicinal products known to be associated with hypotension; or who are dehydrated due to recurrent diarrhoea or vomiting. Management of orthostatic/postural hypotension may include adjustment of antihypertensive medicinal products, rehydration or administration of mineralocorticosteroids and/or sympathomimetics. Patients should be instructed to seek medical advice if they experience symptoms of dizziness, light-headedness or fainting spells.</p><p><u>Posterior Reversible Encephalopathy Syndrome (PRES)</u></p><p>There have been reports of&nbsp;<em>PRES</em>&nbsp;in patients receiving BORVIX.&nbsp;<em>PRES&nbsp;</em>is a rare, often reversible, rapidly evolving neurological condition, which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. Brain imaging, preferably Magnetic Resonance Imaging (MRI), is used to confirm the diagnosis. In patients developing PRES, BORVIX should be discontinued.</p><p><u>Heart failure</u></p><p>Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported during bortezomib treatment. Fluid retention may be a predisposing factor for signs and symptoms of heart failure. Patients with risk factors for or existing heart disease should be closely monitored.</p><p><u>Electrocardiogram investigations</u></p><p>There have been isolated cases of QT-interval prolongation in clinical studies, causality has not been established.</p><p><u>Pulmonary disorders</u></p><p>There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown aetiology such as pneumonitis, interstitial pneumonia, lung infiltration, and acute respiratory distress syndrome (ARDS) in patients receiving BORVIX (see section 4.8). Some of these events have been fatal. A pre-treatment chest radiograph is recommended to serve as a baseline for potential post-treatment pulmonary changes.</p><p>In the event of new or worsening pulmonary symptoms (e.g., cough, dyspnoea), a prompt diagnostic evaluation should be performed and patients treated appropriately. The benefit/risk ratio should be considered prior to continuing BORVIX therapy.</p><p>In a clinical trial, two patients (out of 2) given high-dose cytarabine (2 g/m<sup>2</sup>&nbsp;per day) by continuous infusion over 24 hours with daunorubicin and BORVIX for relapsed acute myelogenous leukaemia died of ARDS early in the course of therapy, and the study was terminated. Therefore, this specific regimen with concomitant administration with high-dose cytarabine (2 g/m<sup>2</sup>&nbsp;per day) by continuous infusion over 24 hours is not recommended.</p><p><u>Renal impairment</u></p><p>Renal complications are frequent in patients with multiple myeloma. Patients with renal impairment should be monitored closely (see sections 4.2 and 5.2).</p><p><u>Hepatic impairment</u></p><p>Bortezomib is metabolised by liver enzymes. Bortezomib exposure is increased in patients with moderate or severe hepatic impairment; these patients should be treated with BORVIX at reduced doses and closely monitored for toxicities (see sections 4.2 and 5.2).</p><p><u>Hepatic reactions</u></p><p>Rare cases of hepatic failure have been reported in patients receiving BORVIX and concomitant medicinal products and with serious underlying medical conditions. Other reported hepatic reactions include increases in liver enzymes, hyperbilirubinaemia, and hepatitis. Such changes may be reversible upon discontinuation of bortezomib (see section 4.8).</p><p><u>Tumour lysis syndrome</u></p><p>Because bortezomib is a cytotoxic agent and can rapidly kill malignant plasma cells and MCL cells, the complications of tumour lysis syndrome may occur. The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.</p><p><u>Concomitant medicinal products</u></p><p>Patients should be closely monitored when given bortezomib in combination with potent CYP3A4-inhibitors. Caution should be exercised when bortezomib is combined with CYP3A4- or CYP2C19 substrates (see section 4.5).</p><p>Normal liver function should be confirmed and caution should be exercised in patients receiving oral hypoglycemics (see section 4.5).</p><p><u>Potentially immunocomplex-mediated reactions</u></p><p>Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly. Bortezomib should be discontinued if serious reactions occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em>&nbsp;studies indicate that bortezomib is a weak inhibitor of the cytochrome P450 (CYP) isozymes 1A2, 2C9, 2C19, 2D6 and 3A4. Based on the limited contribution (7%) of CYP2D6 to the metabolism of bortezomib, the CYP2D6 poor metaboliser phenotype is not expected to affect the overall disposition of bortezomib.</p><p>A drug-drug interaction study assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 35% (CI<sub>90%</sub>&nbsp;[1.032 to 1.772]) based on data from 12 patients. Therefore, patients should be closely monitored when given bortezomib in combination with potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir).</p><p>In a drug-drug interaction study assessing the effect of omeprazole, a potent CYP2C19 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 17 patients.</p><p>A drug-drug interaction study assessing the effect of rifampicin, a potent CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC reduction of 45% based on data from 6 patients. Therefore, the concomitant use of bortezomib with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital and St. John&#39;s Wort) is not recommended, as efficacy may be reduced.</p><p>In the same drug-drug interaction study assessing the effect of dexamethasone, a weaker CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 7 patients.</p><p>A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data from 21 patients. This is not considered clinically relevant.</p><p>During clinical trials, hypoglycemia and hyperglycemia were uncommonly and commonly reported in diabetic patients receiving oral hypoglycemics. Patients on oral antidiabetic agents receiving BORVIX treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraception in males and females</u></p><p>Male and female patients of childbearing potential must use effective contraceptive measures during and for 3 months following treatment.</p><p><u>Pregnancy</u></p><p>No clinical data are available for bortezomib with regard to exposure during pregnancy. The teratogenic potential of bortezomib has not been fully investigated.</p><p>In non-clinical studies, bortezomib had no effects on embryonal/foetal development in rats and rabbits at the highest maternally tolerated doses. Animal studies to determine the effects of bortezomib on parturition and post-natal development were not conducted (see section 5.3). BORVIX should not be used during pregnancy unless the clinical condition of the woman requires treatment with BORVIX.</p><p>If BORVIX is used during pregnancy, or if the patient becomes pregnant while receiving this medicinal product, the patient should be informed of potential for hazard to the foetus.</p><p>Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. Thalidomide is contraindicated during pregnancy and in women of childbearing potential unless all the conditions of the thalidomide pregnancy prevention programme are met. Patients receiving BORVIX in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide. Refer to the Summary of Product Characteristics of thalidomide for additional information.</p><p><u>Breast-feeding</u></p><p>It is not known whether bortezomib is excreted in human milk. Because of the potential for serious adverse reactions in breast-fed infants, breast-feeding should be discontinued during treatment with BORVIX.</p><p><u>Fertility</u></p><p>Fertility studies were not conducted with BORVIX (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BORVIX may have a moderate influence on the ability to drive and use machines. BORVIX may be associated with fatigue very commonly, dizziness commonly, syncope uncommonly and orthostatic/postural hypotension or blurred vision commonly. Therefore, patients must be cautious when driving or using machines and should be advised not to drive or operate machinery if they experience these symptoms (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Serious adverse reactions uncommonly reported during treatment with BORVIX include cardiac failure, tumour lysis syndrome, pulmonary hypertension, posterior reversible encephalopathy syndrome, acute diffuse infiltrative pulmonary disorders and rarely autonomic neuropathy.</p><p>The most commonly reported adverse reactions during treatment with BORVIX are nausea, diarrhoea, constipation, vomiting, fatigue, pyrexia, thrombocytopenia, anaemia, neutropenia, peripheral neuropathy (including sensory), headache, paraesthesia, decreased appetite, dyspnoea, rash, herpes zoster and myalgia.</p><p><u>Tabulated summary of adverse reactions</u></p><p><em>Multiple Myeloma</em></p><p>Undesirable effects in Table 7 were considered by the investigators to have at least a possible or probable causal relationship to BORVIX. These adverse reactions are based on an integrated data set of 5,476 patients of whom 3,996 were treated with BORVIX at 1.3 mg/m<sup>2</sup>&nbsp;and included in Table 7.</p><p>Overall, BORVIX was administered for the treatment of multiple myeloma in 3,974 patients.</p><p>Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are defined as: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Table 7 has been generated using Version 14.1 of the MedDRA.</p><p>Post-marketing adverse reactions not seen in clinical trials are also included.</p><p><em>Table 7: Adverse reactions in patients with Multiple Myeloma treated with BORVIX in clinical trials, and all post-marketing adverse reactions regardless of indication<sup>#</sup></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Incidence</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Herpes zoster (inc disseminated &amp; ophthalmic), Pneumonia*, Herpes simplex*, Fungal infection*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Infection*, Bacterial infections*, Viral infections*, Sepsis (inc septic shock)*, Bronchopneumonia, Herpes virus infection*, Meningoencephalitis herpetic<sup>#</sup>, Bacteraemia (inc staphylococcal), Hordeolum, Influenza, Cellulitis, Device related infection, Skin infection*, Ear infection*, Staphylococcal infection, Tooth infection*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Meningitis (inc bacterial), Epstein-Barr virus infection, Genital herpes, Tonsillitis, Mastoiditis, Post viral fatigue syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Neoplasm malignant, Leukaemia plasmacytic, Renal cell carcinoma, Mass, Mycosis fungoides, Neoplasm benign*</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Thrombocytopenia*, Neutropenia*, Anaemia*</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Leukopenia*, Lymphopenia*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancytopenia*, Febrile neutropenia, Coagulopathy*, Leukocytosis*, Lymphadenopathy, Haemolytic anaemia<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Disseminated intravascular coagulation, Thrombocytosis*, Hyperviscosity syndrome, Platelet disorder NOS, Thrombotic microangiopathy (inc thrombocytopenic purpura)&nbsp;<sup>#</sup>, Blood disorder NOS, Haemorrhagic diathesis, Lymphocytic infiltration</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Angioedema<sup>#</sup>, Hypersensitivity*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic shock, Amyloidosis, Type III immune complex mediated reaction</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cushing&#39;s syndrome*, Hyperthyroidism*, Inappropriate antidiuretic hormone secretion</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypothyroidism</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dehydration, Hypokalaemia*, Hyponatraemia*, Blood glucose abnormal*, Hypocalcaemia*, Enzyme abnormality*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tumour lysis syndrome, Failure to thrive*, Hypomagnesaemia*, Hypophosphataemia*, Hyperkalaemia*, Hypercalcaemia*, Hypernatraemia*, Uric acid abnormal*, Diabetes mellitus*, Fluid retention</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypermagnesaemia*, Acidosis, Electrolyte imbalance*, Fluid overload, Hypochloraemia*, Hypovolaemia, Hyperchloraemia*, Hyperphosphataemia*, Metabolic disorder, Vitamin B complex deficiency, Vitamin B12 deficiency, Gout, Increased appetite, Alcohol intolerance</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Mood disorders and disturbances*, Anxiety disorder*, Sleep disorders and disturbances*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Mental disorder*, Hallucination*, Psychotic disorder*, Confusion*, Restlessness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Suicidal ideation*, Adjustment disorder, Delirium, Libido decreased</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Neuropathies*, Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia*</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Motor neuropathy*, Loss of consciousness (inc syncope), Dizziness*, Dysgeusia*, Lethargy, Headache*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tremor, Peripheral sensorimotor neuropathy, Dyskinesia*, Cerebellar coordination and balance disturbances*, Memory loss (exc dementia)*, Encephalopathy*, Posterior Reversible Encephalopathy Syndrome<sup>#</sup>, Neurotoxicity, Seizure disorders*, Post herpetic neuralgia, Speech disorder*, Restless legs syndrome, Migraine, Sciatica, Disturbance in attention, Reflexes abnormal*, Parosmia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Cerebral haemorrhage*, Haemorrhage intracranial (inc subarachnoid)*, Brain oedema, Transient ischaemic attack, Coma, Autonomic nervous system imbalance, Autonomic neuropathy, Cranial palsy*, Paralysis*, Paresis*, Presyncope, Brain stem syndrome, Cerebrovascular disorder, Nerve root lesion, Psychomotor hyperactivity, Spinal cord compression, Cognitive disorder NOS, Motor dysfunction, Nervous system disorder NOS, Radiculitis, Drooling, Hypotonia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Eye swelling*, Vision abnormal*, Conjunctivitis*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Eye haemorrhage*, Eyelid infection*, Chalazion<sup>#</sup>, Blepharitis<sup>#</sup>, Eye inflammation*, Diplopia, Dry eye*, Eye irritation*, Eye pain, Lacrimation increased, Eye discharge</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Corneal lesion*, Exophthalmos, Retinitis, Scotoma, Eye disorder (inc. eyelid) NOS, Dacryoadenitis acquired, Photophobia, Photopsia, Optic neuropathy<sup>#</sup>, Different degrees of visual impairment (up to blindness)*</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vertigo*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dysacusis (inc tinnitus)*,Hearing impaired (up to and inc deafness), Ear discomfort*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Ear haemorrhage, Vestibular neuronitis, Ear disorder NOS</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cardiac tamponade<sup>#</sup>, Cardio-pulmonary arrest*, Cardiac fibrillation (inc atrial), Cardiac failure (inc left and right ventricular)*, Arrhythmia*, Tachycardia*, Palpitations, Angina pectoris, Pericarditis (inc pericardial effusion)*, Cardiomyopathy*, Ventricular dysfunction*, Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Atrial flutter, Myocardial infarction*, Atrioventricular block*, Cardiovascular disorder (inc cardiogenic shock), Torsade de pointes, Angina unstable, Cardiac valve disorders*, Coronary artery insufficiency, Sinus arrest</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension*, Orthostatic hypotension, Hypertension*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cerebrovascular accident<sup>#</sup>, Deep vein thrombosis*, Haemorrhage*, Thrombophlebitis (inc superficial), Circulatory collapse (inc hypovolaemic shock), Phlebitis, Flushing*, Haematoma (inc perirenal)*, Poor peripheral circulation*, Vasculitis, Hyperaemia (inc ocular)*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Peripheral embolism, Lymphoedema, Pallor, Erythromelalgia, Vasodilatation, Vein discolouration, Venous insufficiency</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea*, Epistaxis, Upper/lower respiratory tract infection*, Cough*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pulmonary embolism, Pleural effusion, Pulmonary oedema (inc acute), Pulmonary alveolar haemorrhage<sup>#</sup>, Bronchospasm, Chronic obstructive pulmonary disease*, Hypoxaemia*, Respiratory tract congestion*, Hypoxia, Pleurisy*, Hiccups, Rhinorrhoea, Dysphonia, Wheezing</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Respiratory failure, Acute respiratory distress syndrome, Apnoea, Pneumothorax, Atelectasis, Pulmonary hypertension, Haemoptysis, Hyperventilation, Orthopnoea, Pneumonitis, Respiratory alkalosis, Tachypnoea, Pulmonary fibrosis, Bronchial disorder*, Hypocapnia*, Interstitial lung disease, Lung infiltration, Throat tightness, Dry throat, Increased upper airway secretion, Throat irritation, Upper-airway cough syndrome</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Nausea and vomiting symptoms*, Diarrhoea*, Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage (inc mucosal)*, Dyspepsia, Stomatitis*, Abdominal distension, Oropharyngeal pain*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder*, Flatulence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancreatitis (inc chronic)*, Haematemesis, Lip swelling*, Gastrointestinal obstruction (inc small intestinal obstruction, ileus)*, Abdominal discomfort, Oral ulceration*, Enteritis*, Gastritis*, Gingival bleeding, Gastrooesophageal reflux disease*, Colitis (inc clostridium difficile)*, Colitis ischaemic<sup>#</sup>, Gastrointestinal inflammation*, Dysphagia, Irritable bowel syndrome, Gastrointestinal disorder NOS, Tongue coated, Gastrointestinal motility disorder*, Salivary gland disorder*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pancreatitis acute, Peritonitis*, Tongue oedema*, Ascites, Oesophagitis, Cheilitis, Faecal incontinence, Anal sphincter atony, Faecaloma*, Gastrointestinal ulceration and perforation*, Gingival hypertrophy, Megacolon, Rectal discharge, Oropharyngeal blistering*, Lip pain, Periodontitis, Anal fissure, Change of bowel habit, Proctalgia, Abnormal faeces</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hepatic enzyme abnormality*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatotoxicity (inc liver disorder), Hepatitis*, Cholestasis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatic failure, Hepatomegaly, Budd-Chiari syndrome, Cytomegalovirus hepatitis, Hepatic haemorrhage, Cholelithiasis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash*, Pruritus*, Erythema, Dry skin</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Erythema multiforme, Urticaria, Acute febrile neutrophilic dermatosis, Toxic skin eruption, Toxic epidermal necrolysis<sup>#</sup>, Stevens-Johnson syndrome<sup>#</sup>, Dermatitis*, Hair disorder*, Petechiae, Ecchymosis, Skin lesion, Purpura, Skin mass*, Psoriasis, Hyperhidrosis, Night sweats, Decubitus ulcer<sup>#</sup>, Acne*, Blister*, Pigmentation disorder*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Skin reaction, Jessner&#39;s lymphocytic infiltration, Palmar-plantar erythrodysaesthesia syndrome, Haemorrhage subcutaneous, Livedo reticularis, Skin induration, Papule, Photosensitivity reaction, Seborrhoea, Cold sweat, Skin disorder NOS, Erythrosis, Skin ulcer, Nail disorder</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Musculoskeletal pain*</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Muscle spasms*, Pain in extremity, Muscular weakness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Muscle twitching, Joint swelling, Arthritis*, Joint stiffness, Myopathies*,Sensation of heaviness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rhabdomyolysis, Temporomandibular joint syndrome, Fistula, Joint effusion, Pain in jaw, Bone disorder, Musculoskeletal and connective tissue infections and inflammations*, Synovial cyst</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal impairment*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Renal failure acute, Renal failure chronic*, Urinary tract infection*, Urinary tract signs and symptoms*, Haematuria*, Urinary retention, Micturition disorder*, Proteinuria, Azotaemia, Oliguria*, Pollakiuria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bladder irritation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vaginal haemorrhage, Genital pain*, Erectile dysfunction,</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Testicular disorder*, Prostatitis, Breast disorder female, Epididymal tenderness, Epididymitis, Pelvic pain, Vulval ulceration</p></td></tr><tr><td style="vertical-align:top"><p>Congenital, familial and genetic disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Aplasia, Gastrointestinal malformation, Ichthyosis</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Pyrexia*, Fatigue, Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oedema (inc peripheral), Chills, Pain*, Malaise*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>General physical health deterioration*, Face oedema*, Injection site reaction*, Mucosal disorder*, Chest pain, Gait disturbance, Feeling cold, Extravasation*, Catheter related complication*, Change in thirst*, Chest discomfort, Feeling of body temperature change*, Injection site pain*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Death (inc sudden), Multi-organ failure, Injection site haemorrhage*, Hernia(inc hiatus)*, Impaired healing*, Inflammation, Injection site phlebitis*, Tenderness, Ulcer, Irritability, Non-cardiac chest pain, Catheter site pain, Sensation of foreign body</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weight decreased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia*, Protein analyses abnormal*, Weight increased, Blood test abnormal*,C-reactive protein increased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Blood gases abnormal*, Electrocardiogram abnormalities (inc QT prolongation)*, International normalised ratio abnormal*, Gastric pH decreased, Platelet aggregation increased, Troponin I increased, Virus identification and serology*, Urine analysis abnormal*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Fall, Contusion</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Transfusion reaction, Fractures*, Rigors*, Face injury, Joint injury*, Burns, Laceration, Procedural pain, Radiation injuries*</p></td></tr><tr><td style="vertical-align:top"><p>Surgical and medical procedures</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Macrophage activation</p></td></tr></tbody></table><p>NOS=not otherwise specified</p><p>* Grouping of more than one MedDRA preferred term.</p><p><sup>#</sup>&nbsp;Post-marketing adverse reaction regardless of indication</p><p><em>Mantle Cell Lymphoma (MCL)</em></p><p>The safety profile of BORVIX in 240 MCL patients treated with BORVIX at 1.3 mg/m<sup>2</sup>&nbsp;in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP) versus 242 patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] was relatively consistent to that observed in patients with multiple myeloma with main differences described below. Additional adverse drug reactions identified associated with the use of the combination therapy (VcR-CAP) were hepatitis B infection (&lt; 1%) and myocardial ischaemia (1.3%). The similar incidences of these events in both treatment arms, indicated that these adverse drug reactions are not attributable to BORVIX alone. Notable differences in the MCL patient population as compared to patients in the multiple myeloma studies were a &ge; 5% higher incidence of the haematological adverse reactions (neutropenia, thrombocytopenia, leukopenia, anemia, lymphopenia), peripheral sensory neuropathy, hypertension, pyrexia, pneumonia, stomatitis, and hair disorders.</p><p>Adverse drug reactions identified as those with a &ge; 1% incidence, similar or higher incidence in the VcR-CAP arm and with at least a possible or probable causal relationship to the components of the VcR-CAP arm, are listed in Table 8 below. Also included are adverse drug reactions identified in the VcR-CAP arm that were considered by investigators to have at least a possible or probable causal relationship to BORVIX based on historical data in the multiple myeloma studies.</p><p>Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are defined as: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Table 8 has been generated using Version 16 of the MedDRA.</p><p><em>Table 8: Adverse reactions in patients with Mantle Cell Lymphoma treated with VcR-CAP in a clinical trial</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Incidence</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Pneumonia*</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sepsis (inc septic shock)*, Herpes zoster (inc disseminated &amp; ophthalmic), Herpes virus infection*, Bacterial infections*, Upper/lower respiratory tract infection*, Fungal infection*, Herpes simplex*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatitis B, Infection*, Bronchopneumonia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancytopenia*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypersensitivity*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypokalaemia*, Blood glucose abnormal*, Hyponatraemia*, Diabetes mellitus*, Fluid retention</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tumour lysis syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sleep disorders and disturbances*</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia*</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Neuropathies*, Motor neuropathy*, Loss of consciousness (inc syncope), Encephalopathy*, Peripheral sensorimotor neuropathy, Dizziness*, Dysgeusia*, Autonomic neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Autonomic nervous system imbalance</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vision abnormal*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dysacusis (inc tinnitus)*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo*, Hearing impaired (up to and inc deafness)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cardiac fibrillation (inc atrial), Arrhythmia*, Cardiac failure (inc left and right ventricular)*, Myocardial ischaemia, Ventricular dysfunction*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cardiovascular disorder (inc cardiogenic shock)</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypertension*, Hypotension*, Orthostatic hypotension</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea*, Cough*, Hiccups</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome, Pulmonary embolism, Pneumonitis, Pulmonary hypertension, Pulmonary oedema (inc acute)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Nausea and vomiting symptoms*, Diarrhoea*, Stomatitis*, Constipation</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage (inc mucosal)*, Abdominal distension, Dyspepsia, Oropharyngeal pain*, Gastritis*, Oral ulceration*, Abdominal discomfort, Dysphagia, Gastrointestinal inflammation*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Colitis (inc clostridium difficile)*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hepatotoxicity (inc liver disorder)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatic failure</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Hair disorder*</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus*, Dermatitis*, Rash*</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Muscle spasms*, Musculoskeletal pain*, Pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Urinary tract infection*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Pyrexia*, Fatigue, Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oedema (inc peripheral), Chills, Injection site reaction*, Malaise*</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia*, Protein analyses abnormal*, Weight decreased, Weight increased</p></td></tr></tbody></table><p>* Grouping of more than one MedDRA preferred term.</p><p><u>Description of selected adverse reactions</u></p><p><em>Herpes zoster virus reactivation</em></p><p>Multiple Myeloma</p><p>Antiviral prophylaxis was administered to 26% of the patients in the Vc+M+P arm. The incidence of herpes zoster among patients in the Vc+M+P treatment group was 17% for patients not administered antiviral prophylaxis compared to 3% for patients administered antiviral prophylaxis.</p><p>Mantle cell lymphoma</p><p>Antiviral prophylaxis was administered to 137 of 240 patients (57%) in the VcR-CAP arm. The incidence of herpes zoster among patients in the VcR-CAP arm was 10.7% for patients not administered antiviral prophylaxis compared to 3.6% for patients administered antiviral prophylaxis (see section 4.4).</p><p><em>Hepatitis B Virus (HBV) reactivation and infection</em></p><p>Mantle cell lymphoma</p><p>HBV infection with fatal outcomes occurred in 0.8% (n=2) of patients in the non-BORVIX treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP ) and 0.4% (n=1) of patients receiving BORVIX in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP). The overall incidence of hepatitis B infections was similar in patients treated with VcR-CAP or with R-CHOP (0.8% vs 1.2% respectively).</p><p><em>Peripheral neuropathy in combination regimens</em></p><p>Multiple Myeloma</p><p>In trials in which BORVIX was administered as induction treatment in combination with dexamethasone (study IFM-2005-01), and dexamethasone-thalidomide (study MMY-3010), the incidence of peripheral neuropathy in the combination regimens is presented in the table below:</p><p><em>Table 9: Incidence of peripheral neuropathy during induction treatment by toxicity and treatment discontinuation due to peripheral neuropathy</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><u>IFM-2005-01</u></p></td><td colspan="2" style="vertical-align:top"><p><u>MMY-3010</u></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>VDDx</p><p>(N=239)</p></td><td style="vertical-align:top"><p>VcDx</p><p>(N=239)</p></td><td style="vertical-align:top"><p>TDx</p><p>(N=126)</p></td><td style="vertical-align:top"><p>VcTDx</p><p>(N=130)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Incidence of PN (%)</p></td></tr><tr><td style="vertical-align:top"><p>All GradePN</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>45</p></td></tr><tr><td style="vertical-align:top"><p>&ge; Grade 2 PN</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>31</p></td></tr><tr><td style="vertical-align:top"><p>&ge; Grade 3 PN</p></td><td style="vertical-align:top"><p>&lt; 1</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Discontinuation due to PN (%)</p></td><td style="vertical-align:top"><p>&lt; 1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>5</p></td></tr></tbody></table><p>VDDx=vincristine, doxorubicin, dexamethasone; VcDx=BORVIX, dexamethasone; TDx=thalidomide, dexamethasone; VcTDx=BORVIX, thalidomide, dexamethasone; PN=peripheral neuropathy</p><p>Note: Peripheral neuropathy included the preferred terms: neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy.</p><p>Mantle cell lymphoma</p><p>In study LYM-3002 in which BORVIX was administered with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CAP), the incidence of peripheral neuropathy in the combination regimens is presented in the table below:</p><p><em>Table 10: Incidence of peripheral neuropathy in study LYM-3002 by toxicity and treatment discontinuation due to peripheral neuropathy</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>VcR-CAP</p><p>(N=240)</p></td><td style="vertical-align:top"><p>R-CHOP</p><p>(N=242)</p></td></tr><tr><td style="vertical-align:top"><p>Incidence of PN (%)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>All GradePN</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>29</p></td></tr><tr><td style="vertical-align:top"><p>&ge; Grade 2 PN</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>&ge; Grade 3 PN</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Discontinuation due to PN (%)</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&lt; 1</p></td></tr></tbody></table><p>VcR-CAP=BORVIX, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy</p><p>Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy</p><p><em>Elderly MCL patients</em></p><p>42.9% and 10.4% of patients in the VcR-CAP arm were in the range 65-74 years and &ge; 75 years of age, respectively. Although in patients aged &ge; 75 years, both VcR-CAP and R-CHOP were less tolerated, the serious adverse event rate in the VcR-CAP groups was 68%, compared to 42% in the R-CHOP group.</p><p><em>Notable differences in the safety profile of BORVIX administered subcutaneously versus intravenously as single agent</em></p><p>In the Phase III study patients who received BORVIX subcutaneously compared to intravenous administration had 13% lower overall incidence of treatment emergent adverse reactions that were Grade 3 or higher in toxicity, and a 5% lower incidence of discontinuation of BORVIX. The overall incidence of diarrhoea, gastrointestinal and abdominal pain, asthenic conditions, upper respiratory tract infections and peripheral neuropathies were 12%-15% lower in the subcutaneous group than in the intravenous group. In addition, the incidence of Grade 3 or higher peripheral neuropathies was 10% lower, and the discontinuation rate due to peripheral neuropathies 8% lower for the subcutaneous group as compared to the intravenous group.</p><p>Six percent of patients had an adverse local reaction to subcutaneous administration, mostly redness. Cases resolved in a median of 6 days, dose modification was required in two patients. Two (1%) of the patients had severe reactions; 1 case of pruritus and 1 case of redness.</p><p>The incidence of death on treatment was 5% in the subcutaneous treatment group and 7% in the intravenous treatment group. Incidence of death from &ldquo;Progressive disease&rdquo; was 18% in the subcutaneous group and 9% in the intravenous group.</p><p><em>Retreatment of patients with relapsed multiple myeloma</em></p><p>In a study in which BORVIX retreatment was administered in 130 patients with relapsed multiple myeloma, who previously had at least partial response on a BORVIX-containing regimen, the most common all-grade adverse events occurring in at least 25% of patients were thrombocytopenia (55%), neuropathy (40%), anaemia (37%), diarrhoea (35%), and constipation (28%). All grade peripheral neuropathy and grade &ge; 3 peripheral neuropathy were observed in 40% and 8.5% of patients, respectively.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:.6pt;margin-top:6pt;width:375.05pt;height:125.4pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAG4df5BwFAAB7HgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWd1u2zYUvh+wdyB0tWFwbMk/SYwq
XerURYE0NeIUu6Yp2iZKkRpJ//VyT7K32P1eaK+wj5SSyG7WZG1u0tgBFEo8OuL5zg/Jjy9ernNJ
ltxYoVUaxQetiHDFdCbULI0+XA0bRxGxjqqMSq14Gm24jV6e/PjDC9qfGVrMBSPQoGyfptHcuaLf
bFo25zm1B7rgCn1TbXLqcGtmzczQFTTnspm0Wr1mToWKTm5VnVFHycKIr1AlNfvIswFVS2qhUrJ+
/Uk1Rsm+XTPtq+UbU4yLkfEjZxfLkSEiSyMgp2gOiKJm1VGJ4ba589bsVsF6anIvr6dTsk6j4yRp
JVC1gTO6STc5bJXq+NoRhv7OYa8dt7sRYUHiOOkeVRJs/v7LKtj89T1KMMxyOGjUhmgLP0C1/Nzm
zrXNV358r/SaJDfWe2ni1ngIU4KXbXEOL1mi9GBO1YyfGqNXc04z6yVKmIBn+ZkA2fUXrdc1Wb3T
GfClC6eDvkeC7sZq2i+MdW+4zolvpJHhzIUv0eW5deUAr0U8JFZLkQ2FlOHGzCYDaciSyjQahl9l
05aYVGQFN8O3JSb/qaIVfnepyIXjhkiRp9HRjRDteyRfqyxEn6NClm1YJ1WIQA+iH6hbj4NDvW+y
jX8ywX8AbDRsRuyhHLj3uEylxlCZFEVE5tp82n3m5ZBQ6InICsUgjezvC2p4RORbBZ8ex50O1Llw
0+ke+rg29Z5JvYcqBlVp5CJSNgcOd3hlURgxm+NLZRQpfYoAmIrKH+XYvRXSurHbSB4ACBb6qMmp
OQ9q0LgMDSpnKHUSY3Hw1HVosld8GtxYsJGzpRdDZgFAW9R6T6fuC3KhF69UWAfADYYhEfBpxFXj
wxgF9RO+iwoYIoBPpwizMr5gBHVCEbcp+JQyBPuVyLm94KtLnVM1Gr+7KvOL05rMgEoxMSIiBVXa
4iVUkGGri6v/67Ta/ope4dh8SHMhUTraeMDm1FgefB4wY7am9NQICoxqKl+1elBWKg2K71UJHGC7
R8udXMAwragkI3w1p0wvxUwAFcbh7oycmcWMjOmUuw0ZcOUMJz9djAY/k74vnkDc6/KauMpG1NDL
b8WUAFQSUN0yMoGRbWDXCfi1P8Mtxny4i9uTccYtdgHPMkc8qLeJ0u4kxwhMnzZltsglkgQPhMrg
ljRqVBL+NanGBfMNJMiIuTJp4riLolTVrbrEIyYYStZiqJWrxet4k090PWC78GCMcI1bh/BpgrvD
nYDd8mU1cU0WmJtMcHEa/fPHX5Ud96dz/LzSeUjXffLLca/XiOMGwG0c9nrJ/0nVh+H1WKVtn6L7
FI0fFnLfzYyL3JEEcyihrpap7aMk2U3UL6xSHobZs0vTm2UN2ap5fuEX5tP9pBoWlvtJdWfJ8fmy
u75GHg/PTklIW78E5qZP4mP8tkLsnhXwPl/vhHi/8t3a/e1Xvl+/kX3dAG0p+9uFv9qc3r3T9zlJ
FmBH1Czs+Lf4IFunjTybMxzexfl8xywBmCsp1MeBFOxjRdSC+LmfTAZjKhg/02yRo1qWjLLhnkDR
ys5FYcHw9D0za95m1/TizbytCnaQgXP41U4zejDTywNL93X2m+meJ1tnkaPXnAV2ShXH95RJhufI
b91k9298YkGS98lqtTrYZ3hgkh+J0H1Ahtfpw5JsN0+IbH/WifP3n1uTYLmfxfX2rGhh+bi4xIlF
eRxWHiZBwh8SNneOXQPLXB0T+7Pd+v3JvwAAAP//AwBQSwMEFAAGAAgAAAAhAOFRNx/PBgAA5hsA
ABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZzW/cRBS/I/E/jHxvs9/NRt1U2c1uA23a
KNkW9Thrz9rTjD3WzGzSvaH2iISEKIgDlbhxQEClVuJS/ppAERSp/wJvZmyvJ+uQtI2gguaQtZ9/
877fm6/LV+7FDB0QISlPel79Ys1DJPF5QJOw590ajy6sekgqnASY8YT0vDmR3pX199+7jNd8RtMJ
xyIYRyQmCBglcg33vEipdG1lRfpAxvIiT0kC36ZcxFjBqwhXAoEPQUDMVhq1WmclxjTx1oGj0oyG
DP4lSmqCz8SeZkNQgmOQfnM6pT4x2GC/rhFyLgdMoAPMeh7wDPjhmNxTHmJYKvjQ82rmz1tZv7yC
17JBTJ0wtjRuZP6ycdmAYL9hZIpwUgitj1rdS5sFfwNgahk3HA4Hw3rBzwCw74OlVpcyz9Zotd7P
eZZA9nGZ96DWrrVcfIl/c0nnbr/fb3czXSxTA7KPrSX8aq3T2mg4eAOy+PYSvtXfGAw6Dt6ALL6z
hB9d6nZaLt6AIkaT/SW0DuholHEvIFPOtirhqwBfrWXwBQqyocguLWLKE3VSrsX4LhcjAGggw4om
SM1TMsU+5OQAxxNBsRaA1wgufbEkXy6RtCwkfUFT1fM+THHilSAvn33/8tkTdHT/6dH9n44ePDi6
/6Nl5IzawklYHvXi28/+fPQx+uPJNy8eflGNl2X8rz988svPn1cDoXwW5j3/8vFvTx8//+rT3797
WAHfEHhSho9pTCS6QQ7RLo/BMOMVV3MyEa82YhxhWh6xkYQSJ1hLqeA/VJGDvjHHLIuOo0efuB68
LaB9VAGvzu46Cu9FYqZoheRrUewAtzlnfS4qvXBNyyq5eTxLwmrhYlbG7WJ8UCV7gBMnvsNZCn0z
T0vH8EFEHDV3GE4UDklCFNLf+D4hFdbdodTx6zb1BZd8qtAdivqYVrpkTCdONi0GbdEY4jKvshni
7fhm+zbqc1Zl9SY5cJFQFZhVKD8mzHHjVTxTOK5iOcYxKzv8OlZRlZJ7c+GXcUOpINIhYRwNAyJl
1ZibAuwtBf0aho5VGfZtNo9dpFB0v4rndcx5GbnJ9wcRjtMq7B5NojL2A7kPKYrRDldV8G3uVoh+
hzjg5MRw36bECffp3eAWDR2VFgmiv8yEjiW0aqcDxzT5u3bMKPRjmwPn146hAT7/+lFFZr2tjXgD
5qSqStg61n5Pwh1vugMuAvr299xNPEt2CKT58sTzruW+a7nef77lnlTPZ220i94KbVevG+yi2CyR
4xNXyFPK2J6aM3JdmkWyhHkiGAFRjzM7QVLsmNIIHrO+7uBCgc0YJLj6iKpoL8IpLLDrnmYSyox1
KFHKJWzsDLmSt8bDIl3ZbWFbbxhsP5BYbfPAkpuanO8LCjZmtgnN5jMX1NQMziqseSljCma/jrC6
VurM0upGNdPqHGmFyRDDZdOAWHgTFiAIli3g5Q7sxbVo2JhgRgLtdzv35mExUTjPEMkIBySLkbZ7
OUZ1E6Q8V8xJAORORYz0Ju8Ur5WkdTXbN5B2liCVxbVOEJdH702ilGfwIkq6bo+VI0vKxckSdNjz
uu1G20M+TnveFPa08BinEHWp13yYhXAa5Cth0/7UYjZVvohmNzfMLYI6HFNYvy8Z7PSBVEi1iWVk
U8N8ylKAJVqS1b/RBreelwE2019Di+YqJMO/pgX40Q0tmU6Jr8rBLlG07+xr1kr5TBGxFwWHaMJm
YhdD+HWqgj0BlXA0YTqCfoFzNO1t88ltzlnRlU+vDM7SMUsjnLVbXaJ5JVu4qeNCB/NWUg9sq9Td
GPfqppiSPydTymn8PzNFzydwUtAMdAR8OJQVGOl67XlcqIhDF0oj6o8ELBxM74BsgbNY+AxJBSfI
5leQA/1ra87yMGUNGz61S0MkKMxHKhKE7EBbMtl3CrN6NndZlixjZDKqpK5MrdoTckDYWPfAjp7b
PRRBqptukrUBgzuef+57VkGTUC9yyvXm9JBi7rU18E+vfGwxg1FuHzYLmtz/hYoVs6odb4bnc2/Z
EP1hscxq5VUBwkpTQTcr+9dU4RWnWtuxlixutHPlIIrLFgOxWBClcN6D9D+Y/6jwmb1t0BPqmO9C
b0Vw0aCZQdpAVl+wCw+kG6QlTmDhZIk2mTQr69ps6aS9lk/W57zSLeQec7bW7CzxfkVnF4szV5xT
i+fp7MzDjq8t7URXQ2SPlyiQpvlGxgSm6tZpG6doEtZ7Htz8QKDvwRPcHXlAa2haQ9PgCS6EYLFk
b3F6XvaQU+C7pRSYZk5p5phWTmnllHZOgcVZdl+SUzrQqfQVB1yx6R8P5bcZsILLbj/ypupcza3/
BQAA//8DAFBLAwQUAAYACAAAACEAU6vb/O0AAADNAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9f
cmVscy9kcmF3aW5nMS54bWwucmVsc6yRwWoDIRBA74X+g8y9uptDKSFucmgLOfRS0g8YdNaVrKOo
CcnfVxpKGwj00suAM/rmObNan8IsjpSLj6yhlx0IYhOtZ6fhY/f68ASiVGSLc2TScKYC6+H+bvVO
M9b2qEw+FdEoXDRMtaalUsVMFLDImIhbZYw5YG3H7FRCs0dHatF1jyr/ZsBwxRRbqyFv7QLE7pxa
57/ZcRy9oedoDoG43mihavOiBsTsqGqQ8pK5xF42V1C3Nfr/1Jjah/Lsef+jEtDPNS45GWnzwW3K
aFG6eJQFvy+9RdvG8HKqlBm/RNXVEoZPAAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4C
AAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0w
P/HBAAAAMgEAAAsAAAAAAAAAAAAAAAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhABuH
X+QcBQAAex4AAB8AAAAAAAAAAAAAAAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54
bWxQSwECLQAUAAYACAAAACEA4VE3H88GAADmGwAAGgAAAAAAAAAAAAAAAAB5BwAAY2xpcGJvYXJk
L3RoZW1lL3RoZW1lMS54bWxQSwECLQAUAAYACAAAACEAU6vb/O0AAADNAQAAKgAAAAAAAAAAAAAA
AACADgAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAF
AAUAZwEAALUPAAAAAA==
">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=right dir=RTL style='text-align:left;mso-layout-grid-align:
    none;text-autospace:none'><span dir=LTR style='font-family:TimesNewRomanPSMT;
    mso-ascii-font-family:TimesNewRomanPSMT;mso-hansi-font-family:TimesNewRomanPSMT'>National
    Pharmacovigilance and Drug Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    TimesNewRomanPSMT;mso-ascii-font-family:TimesNewRomanPSMT;mso-hansi-font-family:
    TimesNewRomanPSMT'>Fax: +966-11-205-7662<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    TimesNewRomanPSMT;mso-ascii-font-family:TimesNewRomanPSMT;mso-hansi-font-family:
    TimesNewRomanPSMT'>Call NPC at +966-11-2038222</span> <span
    style='font-family:TimesNewRomanPSMT;mso-ascii-font-family:TimesNewRomanPSMT;
    mso-hansi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    TimesNewRomanPSMT;mso-ascii-font-family:TimesNewRomanPSMT;mso-hansi-font-family:
    TimesNewRomanPSMT'>SFDA Call Center: 19999<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    class=MsoHyperlink><span style='font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol;text-decoration:none;text-underline:
    none'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span></span><![endif]><span dir=LTR></span><span
    style='font-family:TimesNewRomanPSMT;mso-ascii-font-family:TimesNewRomanPSMT;
    mso-hansi-font-family:TimesNewRomanPSMT'>E-mail: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:TimesNewRomanPSMT;
    mso-ascii-font-family:TimesNewRomanPSMT;mso-hansi-font-family:TimesNewRomanPSMT'>npc.drug@sfda.gov.sa</span></a><span
    class=MsoHyperlink><span style='font-family:TimesNewRomanPSMT;mso-ascii-font-family:
    TimesNewRomanPSMT;mso-hansi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></span></p>
    <p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "Times New Roman",serif'>Website: www.sfda.gov.sa</span><span
    style='font-family:TimesNewRomanPSMT;mso-ascii-font-family:TimesNewRomanPSMT;
    mso-hansi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span dir=LTR><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="173" alt="Text Box: National Pharmacovigilance and Drug Safety Centre (NPC) :
•	Fax: +966-11-205-7662
•	Call NPC at +966-11-2038222 
•	SFDA Call Center: 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.sfda.gov.sa

" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients, overdose more than twice the recommended dose has been associated with the acute onset of symptomatic hypotension and thrombocytopenia with fatal outcomes. For preclinical cardiovascular safety pharmacology studies, see section 5.3.</p><p>There is no known specific antidote for bortezomib overdose. In the event of an overdose, the patient&#39;s vital signs should be monitored and appropriate supportive care given to maintain blood pressure (such as fluids, pressors, and/or inotropic agents) and body temperature (see sections 4.2 and 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XX32.</p><p><u>Mechanism of action</u></p><p>Bortezomib is a proteasome inhibitor. It is specifically designed to inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the turnover of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death.</p><p>Bortezomib is highly selective for the proteasome. At 10 &mu;M concentrations, bortezomib does not inhibit any of a wide variety of receptors and proteases screened and is more than 1,500-fold more selective for the proteasome than for its next preferable enzyme. The kinetics of proteasome inhibition were evaluated&nbsp;<em>in vitro</em>, and bortezomib was shown to dissociate from the proteasome with a t<sub>&frac12;</sub>&nbsp;of 20 minutes, thus demonstrating that proteasome inhibition by bortezomib is reversible.</p><p>Bortezomib mediated proteasome inhibition affects cancer cells in a number of ways, including, but not limited to, altering regulatory proteins, which control cell cycle progression and nuclear factor kappa B (NF-kB) activation. Inhibition of the proteasome results in cell cycle arrest and apoptosis. NF-kB is a transcription factor whose activation is required for many aspects of tumourigenesis, including cell growth and survival, angiogenesis, cell-cell interactions, and metastasis. In myeloma, bortezomib affects the ability of myeloma cells to interact with the bone marrow microenvironment.</p><p>Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types and that cancer cells are more sensitive to the pro-apoptotic effects of proteasome inhibition than normal cells. Bortezomib causes reduction of tumour growth&nbsp;<em>in vivo</em>&nbsp;in many preclinical tumour models, including multiple myeloma.</p><p>Data from&nbsp;<em>in vitro</em>,&nbsp;<em>ex-vivo</em>, and animal models with bortezomib suggest that it increases osteoblast differentiation and activity and inhibits osteoclast function. These effects have been observed in patients with multiple myeloma affected by an advanced osteolytic disease and treated with bortezomib.</p><p><u>Clinical efficacy in previously untreated multiple myeloma</u></p><p>A prospective Phase III, international, randomised (1:1), open-label clinical study (MMY-3002 VISTA) of 682 patients was conducted to determine whether BORVIX (1.3 mg/m<sup>2</sup>&nbsp;injected intravenously) in combination with melphalan (9 mg/m<sup>2</sup>) and prednisone (60 mg/m<sup>2</sup>) resulted in improvement in time to progression (TTP) when compared to melphalan (9 mg/m<sup>2</sup>) and prednisone (60 mg/m<sup>2</sup>) in patients with previously untreated multiple myeloma. Treatment was administered for a maximum of 9 cycles (approximately 54 weeks) and was discontinued early for disease progression or unacceptable toxicity. The median age of the patients in the study was 71 years, 50% were male, 88% were Caucasian and the median Karnofsky performance status score for the patients was 80. Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105 g/l, and a median platelet count of 221.5 x 10<sup>9</sup>/l. Similar proportions of patients had creatinine clearance &le; 30 ml/min (3% in each arm).</p><p>At the time of a pre-specified interim analysis, the primary endpoint, time to progression, was met and patients in the M+P arm were offered Vc+M+P treatment. Median follow-up was 16.3 months. The final survival update was performed with a median duration of follow-up of 60.1 months. A statistically significant survival benefit in favour of the Vc+M+P treatment group was observed (HR=0.695; p=0.00043) despite subsequent therapies including BORVIX-based regimens. Median survival for the Vc+M+P treatment group was 56.4 months compared to 43.1 for the M+P treatment group. Efficacy results are presented in Table 11:</p><p><em>Table 11: Efficacy results following the final survival update to VISTA study</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Vc+M+P</strong></p><p><strong>n=344</strong></p></td><td style="vertical-align:top"><p><strong>M+P</strong></p><p><strong>n=338</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to progression</strong></p><p>Events n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>101 (29)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>152 (45)</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>a</sup>&nbsp;(95% CI)</p></td><td style="vertical-align:top"><p>20.7 mo</p><p>(17.6, 24,7)</p></td><td style="vertical-align:top"><p>15.0 mo</p><p>(14.1, 17.9)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>b</sup></p><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.54</p><p>(0.42, 0.70)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.000002</p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression-free survival</strong></p><p>Events n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>135 (39)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>190 (56)</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>a</sup>&nbsp;(95% CI)</p></td><td style="vertical-align:top"><p>18.3 mo</p><p>(16.6, 21.7)</p></td><td style="vertical-align:top"><p>14.0 mo</p><p>(11.1, 15.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>b</sup></p><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.61</p><p>(0.49, 0.76)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>&nbsp;c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.00001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall survival*</strong></p><p>Events (deaths) n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>176 (51.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>211 (62.4)</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>a</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>56.4 mo</p><p>(52.8, 60.9)</p></td><td style="vertical-align:top"><p>43.1 mo</p><p>(35.3, 48.3)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>b</sup></p><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.695</p><p>(0.567, 0.852)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.00043</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response rate</strong></p><p>population<sup>e</sup>&nbsp;n=668</p></td><td style="vertical-align:top"><p>n=337</p></td><td style="vertical-align:top"><p>n=331</p></td></tr><tr><td style="vertical-align:top"><p>CR<sup>f</sup>&nbsp;n (%)</p></td><td style="vertical-align:top"><p>102 (30)</p></td><td style="vertical-align:top"><p>12 (4)</p></td></tr><tr><td style="vertical-align:top"><p>PR<sup>f</sup>&nbsp;n (%)</p></td><td style="vertical-align:top"><p>136 (40)</p></td><td style="vertical-align:top"><p>103 (31)</p></td></tr><tr><td style="vertical-align:top"><p>nCR n (%)</p></td><td style="vertical-align:top"><p>5 (1)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>CR+PR<sup>f</sup>&nbsp;n (%)</p></td><td style="vertical-align:top"><p>238 (71)</p></td><td style="vertical-align:top"><p>115 (35)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt; 10<sup>-10</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Reduction in serum M-protein</strong></p><p>population<sup>g</sup>&nbsp;n=667</p></td><td style="vertical-align:top"><p>n=336</p></td><td style="vertical-align:top"><p>n=331</p></td></tr><tr><td style="vertical-align:top"><p>&ge;90% n (%)</p></td><td style="vertical-align:top"><p>151 (45)</p></td><td style="vertical-align:top"><p>34 (10)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to first response in CR + PR</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Median</p></td><td style="vertical-align:top"><p>1.4 mo</p></td><td style="vertical-align:top"><p>4.2 mo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Median</strong><sup>a</sup><strong>&nbsp;response duration</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>CR<sup>f</sup></p></td><td style="vertical-align:top"><p>24.0 mo</p></td><td style="vertical-align:top"><p>12.8 mo</p></td></tr><tr><td style="vertical-align:top"><p>CR+PR<sup>f</sup></p></td><td style="vertical-align:top"><p>19.9 mo</p></td><td style="vertical-align:top"><p>13.1 mo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to next therapy</strong></p><p>Events n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>224 (65.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>260 (76.9)</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>a</sup></p><p>(95% CI)</p></td><td style="vertical-align:top"><p>27.0 mo</p><p>(24.7, 31.1)</p></td><td style="vertical-align:top"><p>19.2 mo</p><p>(17.0, 21.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>b</sup></p><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.557</p><p>(0.462, 0.671)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.000001</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Kaplan-Meier estimate.</p><p><sup>b</sup>&nbsp;Hazard ratio estimate is based on a Cox proportional-hazard model adjusted for stratification factors: &beta;<sub>2</sub>-microglobulin, albumin, and region. A hazard ratio less than 1 indicates an advantage for VMP</p><p><sup>c</sup>&nbsp;Nominal p-value based on the stratified log-rank test adjusted for stratification factors: &beta;<sub>2</sub>-microglobulin, albumin, and region</p><p><sup>d</sup>&nbsp;p-value for Response Rate (CR+PR) from the Cochran Mantel-Haenszel chi-square test adjusted for the stratification factors</p><p><sup>e</sup>&nbsp;Response population includes patients who had measurable disease at baseline</p><p><sup>f</sup>&nbsp;CR=Complete Response; PR=Partial Response. EBMT criteria</p><p><sup>g</sup>&nbsp;All randomised patients with secretory disease</p><p>* Survival update based on a median duration of follow-up at 60.1 months</p><p>mo: months</p><p>CI=Confidence Interval</p><p><em>Patients eligible for stem cell transplantation</em></p><p>Two randomised, open-label, multicenter Phase III trials (IFM-2005-01, MMY-3010) were conducted to demonstrate the safety and efficacy of BORVIX in dual and triple combinations with other chemotherapeutic agents, as induction therapy prior to stem cell transplantation in patients with previously untreated multiple myeloma.</p><p>In study IFM-2005-01 BORVIX combined with dexamethasone [VcDx, n=240] was compared to vincristine- doxorubicin-dexamethasone [VDDx, n=242]. Patients in the VcDx group received four 21 day cycles, each consisting of BORVIX (1.3 mg/m<sup>2</sup>&nbsp;administered intravenously twice weekly on days 1, 4, 8, and 11), and oral dexamethasone (40 mg/day on days 1 to 4 and days 9 to 12, in Cycles 1 and 2, and on days 1 to 4 in Cycles 3 and 4).</p><p>Autologous stem cell transplants were received by 198 (82%) patients and 208 (87%) patients in the VDDx and VcDx groups respectively; the majority of patients underwent one single transplant procedure. Patient demographic and baseline disease charateristics were similar between the treatment groups. Median age of the patients in the study was 57 years, 55% were male and 48% of patients had high-risk cytogenetics. The median duration of treatment was 13 weeks for the VDDx group and 11 weeks for the VcDx group. The median number of cycles received for both groups was 4 cycles.</p><p>The primary efficacy endpoint of the study was post-induction response rate (CR+nCR). A statistically significant difference in CR+nCR was observed in favour of the BORVIX combined with dexamethasone group. Secondary efficacy endpoints included post-transplant response rates (CR+nCR, CR+nCR+VGPR+PR), Progression Free Survival and Overall Survival. Main efficacy results are presented in Table 12.</p><p><em>Table 12: Efficacy results from study IFM-2005-01</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>VcDx</strong></p></td><td style="vertical-align:top"><p><strong>VDDx</strong></p></td><td style="vertical-align:top"><p><strong>OR; 95% CI; P value<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>IFM-2005-01</strong></p></td><td style="vertical-align:top"><p>N=240 (ITT population)</p></td><td style="vertical-align:top"><p>N=242 (ITT population)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>RR (Post-induction)</em></p><p>*CR+nCR</p><p>CR+nCR+VGPR+PR % (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>14.6 (10.4, 19.7)</p><p>77.1 (71.2, 82.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>6.2 (3.5, 10.0)</p><p>60.7 (54.3, 66.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.58 (1.37, 4.85); 0.003</p><p>2.18 (1.46, 3.24); &lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p><em>RR (Post-transplant)<sup>b</sup></em></p><p>CR+nCR</p><p>CR+nCR+VGPR+PR % (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>37.5 (31.4, 44.0)</p><p>79.6 (73.9, 84.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23.1 (18.0, 29.0)</p><p>74.4 (68.4, 79.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.98 (1.33, 2.95); 0.001</p><p>1.34 (0.87, 2.05); 0.179</p></td></tr></tbody></table><p>CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Vc=BORVIX; VcDx=BORVIX, dexamethasone; VDDx=vincristine, doxorubicin, dexamethasone; VGPR=very good partial response; PR=partial response; OR=odds ratio.</p><p>* Primary endpoint</p><p><sup>a</sup>&nbsp;OR for response rates based on Mantel-Haenszel estimate of the common odds ratio for stratified tables; p-values by Cochran Mantel-Haenszel test.</p><p><sup>b</sup>&nbsp;Refers to response rate after second transplant for subjects who received a second transplant (42/240 [18% ] in VcDx group and 52/242 [21%] in VDDx group).</p><p>Note: An OR &gt; 1 indicates an advantage for Vc-containing induction therapy.</p><p>In study MMY-3010 induction treatment withBORVIX combined with thalidomide and dexamethasone [VcTDx, n=130] was compared to thalidomide-dexamethasone [TDx, n=127]. Patients in the VcTDx group received six 4-week cycles, each consisting of BORVIX (1.3 mg/m<sup>2</sup>&nbsp;administered twice weekly days 1, 4, 8, and 11, followed by a 17-day rest period from day 12 to day 28), dexamethasone (40 mg administered orally on days 1 to 4 and days 8 to 11), and thalidomide (administered orally at 50 mg daily on days 1-14, increased to 100 mg on days 15-28 and thereafter to 200 mg daily).</p><p>One single autologous stem cell transplant was received by 105 (81%) patients and 78 (61%) patients in the VcTDx and TDx groups, respectively. Patient demographic and baseline disease charateristics were similar between the treatment groups. Patients in the VcTDx and TDx groups respectively had a median age of 57 versus 56 years, 99% versus 98% patients were Caucasians, and 58% versus 54% were males. In the VcTDx group 12% of patients were cytogenetically classified as high risk versus 16% of patients in the TDx group. The median duration of treatment was 24.0 weeks and the median number of treatment cycles received was 6.0, and was consistent across treatment groups.</p><p>The primary efficacy endpoints of the study were post-induction and post-transplant response rates (CR+nCR). A statistically significant difference in CR+nCR was observed in favour of the BORVIX combined with dexamethasone and thalidomide group. Secondary efficacy endpoints included Progression Free Survival and Overall Survival. Main efficacy results are presented in Table 13.</p><p><em>Table 13: Efficacy results from study MMY-3010</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>VcTDx</strong></p></td><td style="vertical-align:top"><p><strong>TDx</strong></p></td><td style="vertical-align:top"><p><strong>OR; 95% CI; P value<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MMY-3010</strong></p></td><td style="vertical-align:top"><p>N=130 (ITT population)</p></td><td style="vertical-align:top"><p>N=127 (ITT population)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>*RR (Post-induction)</em></p><p>CR+nCR</p><p>CR+nCR+PR % (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>49.2 (40.4, 58.1)</p><p>84.6 (77.2, 90.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>17.3 (11.2, 25.0)</p><p>61.4 (52.4, 69.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.63 (2.61, 8.22); &lt; 0.001<sup>a</sup></p><p>3.46 (1.90, 6.27); &lt; 0.001<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>*RR (Post-transplant)</em></p><p>CR+nCR</p><p>CR+nCR+PR % (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>55.4 (46.4, 64.1)</p><p>77.7 (69.6, 84.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>34.6 (26.4, 43.6)</p><p>56.7 (47.6, 65.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.34 (1.42, 3.87); 0.001<sup>a</sup></p><p>2.66 (1.55, 4.57); &lt; 0.001<sup>a</sup></p></td></tr></tbody></table><p>CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Vc=BORVIX; VcTDx=BORVIX, thalidomide, dexamethasone; TDx=thalidomide, dexamethasone; PR=partial response; OR=odds ratio</p><p>* Primary endpoint</p><p><sup>a</sup>&nbsp;OR for response rates based on Mantel-Haenszel estimate of the common odds ratio for stratified tables; p-values by Cochran Mantel-Haenszel test.</p><p>Note: An OR &gt; 1 indicates an advantage for Vc-containing induction therapy</p><p><u>Clinical efficacy in relapsed or refractory multiple myeloma</u></p><p>The safety and efficacy of BORVIX (injected intravenously) were evaluated in 2 studies at the recommended dose of 1.3 mg/m<sup>2</sup>: a Phase III randomised, comparative study (APEX), versus dexamethasone (Dex), of 669 patients with relapsed or refractory multiple myeloma who had received 1-3 prior lines of therapy, and a Phase II single-arm study of 202 patients with relapsed and refractory multiple myeloma, who had received at least 2 prior lines of treatment and who were progressing on their most recent treatment.</p><p>In the Phase III study, treatment with BORVIX led to a significantly longer time to progression, a significantly prolonged survival and a significantly higher response rate, compared to treatment with dexamethasone (see Table 14), in all patients as well as in patients who have received 1 prior line of therapy. As a result of a pre-planned interim analysis, the dexamethasone arm was halted at the recommendation of the data monitoring committee and all patients randomised to dexamethasone were then offered BORVIX, regardless of disease status. Due to this early crossover, the median duration of follow-up for surviving patients is 8.3 months. Both in patients who were refractory to their last prior therapy and those who were not refractory, overall survival was significantly longer and response rate was significantly higher on the BORVIX arm.</p><p>Of the 669 patients enrolled, 245 (37%) were 65 years of age or older. Response parameters as well as TTP remained significantly better for BORVIX independently of age. Regardless of &beta;<sub>2</sub>-microglobulin levels at baseline, all efficacy parameters (time to progression and overall survival, as well as response rate) were significantly improved on the BORVIX arm.</p><p>In the refractory population of the Phase II study, responses were determined by an independent review committee and the response criteria were those of the European Bone Marrow Transplant Group. The median survival of all patients enrolled was 17 months (range &lt; 1 to 36+ months). This survival was greater than the six-to-nine month median survival anticipated by consultant clinical investigators for a similar patient population. By multivariate analysis, the response rate was independent of myeloma type, performance status, chromosome 13 deletion status, or the number or type of previous therapies. Patients who had received 2 to 3 prior therapeutic regimens had a response rate of 32% (10/32) and patients who received greater than 7 prior therapeutic regimens had a response rate of 31% (21/67).</p><p><em>Table 14: Summary of disease outcomes from the Phase III (APEX) and Phase II studies</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><strong>Phase III</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Phase III</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Phase III</strong></p></td><td style="vertical-align:top"><p><strong>Phase II</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p><strong>All patients</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>1 prior line of therapy</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&gt; 1 prior line of therapy</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 2 prior lines</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Time related events</strong></p></td><td style="vertical-align:top"><p><strong>Vc</strong></p><p><strong>n=333<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Dex</strong></p><p><strong>n=336<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Vc</strong></p><p><strong>n=132<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Dex</strong></p><p><strong>n=119<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Vc</strong></p><p><strong>n=200<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Dex</strong></p><p><strong>n=217<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Vc</strong></p><p><strong>n=202<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>TTP, days</p><p>[95% CI]</p></td><td style="vertical-align:top"><p>189<sup>b</sup></p><p>[148, 211]</p></td><td style="vertical-align:top"><p>106<sup>b</sup></p><p>[86, 128]</p></td><td style="vertical-align:top"><p>212<sup>d</sup></p><p>[188, 267]</p></td><td style="vertical-align:top"><p>169<sup>d</sup></p><p>[105, 191]</p></td><td style="vertical-align:top"><p>148<sup>b</sup></p><p>[129, 192]</p></td><td style="vertical-align:top"><p>87<sup>b</sup></p><p>[84, 107]</p></td><td style="vertical-align:top"><p>210</p><p>[154, 281]</p></td></tr><tr><td style="vertical-align:top"><p>1 year survival, %</p><p>[95% CI]</p></td><td style="vertical-align:top"><p>80<sup>d</sup></p><p>[74,85]</p></td><td style="vertical-align:top"><p>66<sup>d</sup></p><p>[59,72]</p></td><td style="vertical-align:top"><p>89<sup>d</sup></p><p>[82,95]</p></td><td style="vertical-align:top"><p>72<sup>d</sup></p><p>[62,83]</p></td><td style="vertical-align:top"><p>73</p><p>[64,82]</p></td><td style="vertical-align:top"><p>62</p><p>[53,71]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>60</p></td></tr><tr><td style="vertical-align:top"><p><strong>Best response (%)</strong></p></td><td style="vertical-align:top"><p><strong>Vc</strong></p><p><strong>n=315</strong><sup>c</sup></p></td><td style="vertical-align:top"><p><strong>Dex</strong></p><p><strong>n=312</strong><sup>c</sup></p></td><td style="vertical-align:top"><p><strong>Vc</strong></p><p><strong>n=128</strong></p></td><td style="vertical-align:top"><p><strong>Dex</strong></p><p><strong>n=110</strong></p></td><td style="vertical-align:top"><p><strong>Vc</strong></p><p><strong>n=187</strong></p></td><td style="vertical-align:top"><p><strong>Dex</strong></p><p><strong>n=202</strong></p></td><td style="vertical-align:top"><p><strong>Vc</strong></p><p><strong>n=193</strong></p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>20 (6)<sup>b</sup></p></td><td style="vertical-align:top"><p>2 (&lt; 1)<sup>b</sup></p></td><td style="vertical-align:top"><p>8 (6)</p></td><td style="vertical-align:top"><p>2 (2)</p></td><td style="vertical-align:top"><p>12 (6)</p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>(4)**</p></td></tr><tr><td style="vertical-align:top"><p>CR+nCR</p></td><td style="vertical-align:top"><p>41 (13)<sup>b</sup></p></td><td style="vertical-align:top"><p>5 (2)<sup>b</sup></p></td><td style="vertical-align:top"><p>16 (13)</p></td><td style="vertical-align:top"><p>4 (4)</p></td><td style="vertical-align:top"><p>25 (13)</p></td><td style="vertical-align:top"><p>1 (&lt; 1)</p></td><td style="vertical-align:top"><p>(10)**</p></td></tr><tr><td style="vertical-align:top"><p>CR+nCR+PR</p></td><td style="vertical-align:top"><p>121 (38)<sup>b</sup></p></td><td style="vertical-align:top"><p>56 (18)<sup>b</sup></p></td><td style="vertical-align:top"><p>57 (45)<sup>d</sup></p></td><td style="vertical-align:top"><p>29 (26)<sup>d</sup></p></td><td style="vertical-align:top"><p>64 (34)<sup>b</sup></p></td><td style="vertical-align:top"><p>27 (13)<sup>b</sup></p></td><td style="vertical-align:top"><p>(27)**</p></td></tr><tr><td style="vertical-align:top"><p>CR+nCR+ PR+MR</p></td><td style="vertical-align:top"><p>146 (46)</p></td><td style="vertical-align:top"><p>108 (35)</p></td><td style="vertical-align:top"><p>66 (52)</p></td><td style="vertical-align:top"><p>45 (41)</p></td><td style="vertical-align:top"><p>80 (43)</p></td><td style="vertical-align:top"><p>63 (31)</p></td><td style="vertical-align:top"><p>(35)**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Median duration</strong></p><p>Days (months)</p></td><td style="vertical-align:top"><p>242 (8.0)</p></td><td style="vertical-align:top"><p>169 (5.6)</p></td><td style="vertical-align:top"><p>246 (8.1)</p></td><td style="vertical-align:top"><p>189 (6.2)</p></td><td style="vertical-align:top"><p>238 (7.8)</p></td><td style="vertical-align:top"><p>126 (4.1)</p></td><td style="vertical-align:top"><p>385*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to response</strong></p><p>CR+PR (days)</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>38*</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Intent to Treat (ITT) population</p><p><sup>b</sup>&nbsp;p-value from the stratified log-rank test; analysis by line of therapy excludes stratification for therapeutic history; p &lt; 0.0001</p><p><sup>c</sup>&nbsp;Response population includes patients who had measurable disease at baseline and received at least 1 dose of study medicinal product.</p><p><sup>d</sup>&nbsp;p-value from the Cochran Mantel-Haenszel chi-square test adjusted for the stratification factors; analysis by line of therapy excludes stratification for therapeutic history</p><p>* CR+PR+MR **CR=CR, (IF-); nCR=CR (IF+)</p><p>NA=not applicable, NE=not estimated</p><p>TTP-Time to Progression</p><p>CI=Confidence Interval</p><p>Vc=BORVIX; Dex=dexamethasone</p><p>CR=Complete Response; nCR=near Complete response</p><p>PR=Partial Response; MR=Minimal response</p><p>In the Phase II study, patients who did not obtain an optimal response to therapy with BORVIX alone were able to receive high-dose dexamethasone in conjunction with BORVIX. The protocol allowed patients to receive dexamethasone if they had had a less than optimal response to BORVIX alone. A total of 74 evaluable patients were administered dexamethasone in combination with BORVIX. Eighteen percent of patients achieved, or had an improved response [MR (11%) or PR (7%)] with combination treatment.</p><p><em>Clinical efficacy with subcutaneous administration of BORVIX in patients with relapsed/refractory multiple myeloma</em></p><p>An open label, randomised, Phase III non-inferiority study compared the efficacy and safety of the subcutaneous administration of BORVIX versus the intravenous administration. This study included 222 patients with relapsed/refractory multiple myeloma, who were randomised in a 2:1 ratio to receive 1.3 mg/m<sup>2</sup>&nbsp;of BORVIX by either the subcutaneous or intravenous route for 8 cycles. Patients who did not obtain an optimal response (less than Complete Response [CR]) to therapy with BORVIX alone after 4 cycles were allowed to receive dexamethasone 20 mg daily on the day of and after BORVIX administration. Patients with baseline Grade &ge; 2 peripheral neuropathy or platelet counts &lt; 50,000/&micro;l were excluded. A total of 218 patients were evaluable for response.</p><p>This study met its primary objective of non-inferiority for response rate (CR+PR) after 4 cycles of single agent BORVIX for both the subcutaneous and intravenous routes, 42% in both groups. In addition, secondary response-related and time to event related efficacy endpoints showed consistent results for subcutaneous and intravenous administration (Table 15).</p><p><em>Table 15: Summary of efficacy analyses comparing subcutaneous and intravenous administrations of BORVIX</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>BORVIX intravenous arm</strong></p></td><td style="vertical-align:top"><p><strong>BORVIX subcutaneous arm</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Response Evaluable Population</strong></p></td><td style="vertical-align:top"><p><strong>n=73</strong></p></td><td style="vertical-align:top"><p><strong>n=145</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Response Rate at 4 cycles n (%)</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>ORR (CR+PR)</p></td><td style="vertical-align:top"><p>31 (42)</p></td><td style="vertical-align:top"><p>61 (42)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.00201</p></td></tr><tr><td style="vertical-align:top"><p>CR n (%)</p></td><td style="vertical-align:top"><p>6 (8)</p></td><td style="vertical-align:top"><p>9 (6)</p></td></tr><tr><td style="vertical-align:top"><p>PR n (%)</p></td><td style="vertical-align:top"><p>25 (34)</p></td><td style="vertical-align:top"><p>52 (36)</p></td></tr><tr><td style="vertical-align:top"><p>nCR n (%)</p></td><td style="vertical-align:top"><p>4 (5)</p></td><td style="vertical-align:top"><p>9 (6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response Rate at 8 cycles n (%)</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>ORR (CR+PR)</p></td><td style="vertical-align:top"><p>38 (52)</p></td><td style="vertical-align:top"><p>76 (52)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0001</p></td></tr><tr><td style="vertical-align:top"><p>CR n (%)</p></td><td style="vertical-align:top"><p>9 (12)</p></td><td style="vertical-align:top"><p>15 (10)</p></td></tr><tr><td style="vertical-align:top"><p>PR n (%)</p></td><td style="vertical-align:top"><p>29 (40)</p></td><td style="vertical-align:top"><p>61 (42)</p></td></tr><tr><td style="vertical-align:top"><p>nCR n (%)</p></td><td style="vertical-align:top"><p>7 (10)</p></td><td style="vertical-align:top"><p>14 (10)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Intent to Treat Population</strong><sup>b</sup></p></td><td style="vertical-align:top"><p><strong>n=74</strong></p></td><td style="vertical-align:top"><p><strong>n=148</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>TTP, months</strong></p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>10.4</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(7.6, 10.6)</p></td><td style="vertical-align:top"><p>(8.5, 11.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>c</sup></p><p>p-value<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.839 (0.564, 1.249)</p><p>0.38657</p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression Free Survival, months</strong></p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>10.2</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(6.7, 9.8)</p></td><td style="vertical-align:top"><p>(8.1, 10.8)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>c</sup></p><p>p-value<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.824 (0.574, 1.183)</p><p>0.295</p></td></tr><tr><td style="vertical-align:top"><p><strong>1-year Overall Survival (%)</strong><sup>e</sup></p></td><td style="vertical-align:top"><p>76.7</p></td><td style="vertical-align:top"><p>72.6</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(64.1, 85.4)</p></td><td style="vertical-align:top"><p>(63.1, 80.0)</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;p-value is for the non-inferiority hypothesis that the SC arm retains at least 60% of the response rate in the IV arm.</p><p><sup>b</sup>&nbsp;222 subjects were enrolled into the study; 221 subjects were treated with BORVIX</p><p><sup>c</sup>&nbsp;Hazards ratio estimate is based on a Cox model adjusted for stratification factors: ISS staging and number of prior lines.</p><p><sup>d</sup>&nbsp;Log rank test adjusted for stratification factors: ISS staging and number of prior lines.</p><p><sup>e</sup>&nbsp;Median duration of follow up is 11.8 months</p><p><em>BORVIX combination treatment with pegylated liposomal doxorubicin (study DOXIL-MMY-3001)</em></p><p>A Phase III randomised, parallel-group, open-label, multicentre study was conducted in 646 patients comparing the safety and efficacy of BORVIX plus pegylated liposomal doxorubicin versus BORVIX monotherapy in patients with multiple myeloma who had received at least 1 prior therapy and who did not progress while receiving anthracycline-based therapy. The primary efficacy endpoint was TTP while the secondary efficacy endpoints were OS and ORR (CR+PR), using the European Group for Blood and Marrow Transplantation (EBMT) criteria.</p><p>A protocol<em>-</em>defined interim analysis (based on 249 TTP events) triggered early study termination for efficacy. This interim analysis showed a TTP risk reduction of 45% (95% CI; 29<em>-</em>57%, p &lt; 0.0001) for patients treated with combination therapy of BORVIX and pegylated liposomal doxorubicin. The median TTP was 6.5 months for the BORVIX monotherapy patients compared with 9.3 months for the BORVIX plus pegylated liposomal doxorubicin combination therapy patients. These results, though not mature, constituted the protocol defined final analysis.</p><p>The final analysis for OS performed after a median follow-up of 8.6 years showed no significant difference in OS between the two treatment arms. The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the BORVIX monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the BORVIX plus pegylated liposomal doxorubicin combination therapy patients.</p><p><em>BORVIX combination treatment with dexamethasone</em></p><p>In the absence of any direct comparison between BORVIX and BORVIX in combination with dexamethasone in patients with progressive multiple myeloma, a statistical matched-pair analysis was conducted to compare results from the non randomised arm of BORVIX in combination with dexamethasone (Phase II open<em>-</em>label study MMY-2045), with results obtained in the BORVIX monotherapy arms from different Phase III randomised studies (M34101-039 [APEX] and DOXIL MMY-3001) in the same indication.</p><p>The matched-pair analysis is a statistical method in which patients in the treatment group (e.g. BORVIX in combination with dexamethasone) and patients in the comparison group (e.g. BORVIX) are made comparable with respect to confounding factors by individually pairing study subjects. This minimises the effects of observed confounders when estimating treatment effects using non-randomised data.</p><p>One hundred and twenty seven matched pairs of patients were identified. The analysis demonstrated improved ORR (CR+PR) (odds ratio 3.769; 95% CI 2.045-6.947; p &lt; 0.001), PFS (hazard ratio 0.511; 95% CI 0.309-0.845; p=0.008), TTP (hazard ratio 0.385; 95% CI 0.212-0.698; p=0.001) for BORVIX in combination with dexamethasone over BORVIX monotherapy.</p><p>Limited information on BORVIX retreatment in relapsed multiple myeloma is available.</p><p>Phase II study MMY-2036 (RETRIEVE), single arm, open-label study was conducted to determine the efficacy and safety of retreatment with BORVIX. One hundred and thirty patients (&ge; 18 years of age) with multiple myeloma who previously had at least partial response on a BORVIX-containing regimen were retreated upon progression. At least 6 months after prior therapy, BORVIX was started at the last tolerated dose of 1.3 mg/m<sup>2</sup>&nbsp;(n=93) or &le; 1.0 mg/m<sup>2</sup>&nbsp;(n=37) and given on days 1, 4, 8 and 11 every 3 weeks for maximum of 8 cycles either as single agent or in combination with dexamethasone in accordance with the standard of care. Dexamethasone was administered in combination with BORVIX to 83 patients in Cycle 1 with an additional 11 patients receiving dexamethasone during the course of BORVIX retreatment cycles.</p><p>The primary endpoint was best confirmed response to retreatment as assessed by EBMT criteria. The overall best response rate (CR + PR), to retreatment in 130 patients was 38.5% (95% CI: 30.1, 47.4).</p><p><u>Clinical efficacy in previously untreated mantle cell lymphoma (MCL)</u></p><p>Study LYM-3002 was a Phase III, randomised, open-label study comparing the efficacy and safety of the combination of BORVIX, rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV). Patients in the VcR-CAP treatment arm received BORVIX (1.3 mg/m<sup>2</sup>; on days 1, 4, 8, 11, rest period days 12-21), rituximab 375 mg/m<sup>2</sup>&nbsp;IV on day 1; cyclophosphamide 750 mg/m<sup>2</sup>&nbsp;IV on day 1; doxorubicin 50 mg/m<sup>2</sup>&nbsp;IV on day 1; and prednisone 100 mg/m<sup>2</sup>&nbsp;orally on day 1 through day 5 of the 21 day BORVIX treatment cycle. For patients with a response first documented at cycle 6, two additional treatment cycles were given.</p><p>The primary efficacy endpoint was progression-free survival based on Independent Review Committee (IRC) assessment. Secondary endpoints included, time to progression (TTP), time to next anti-lymphoma treatment (TNT), duration of treatment free interval (TFI), overall response rate (ORR) and complete response (CR/CRu) rate, overall survival (OS) and response duration.</p><p>The demographic and baseline disease characteristics were generally well balanced between the two treatment arms: median patient age was 66 years, 74% were male, 66% were Caucasian and 32% Asian, 69% of patients had a positive bone marrow aspirate and/or a positive bone marrow biopsy for MCL, 54% of patients had an International Prognostic Index (IPI) score of &ge; 3, and 76% had Stage IV disease. Treatment duration (median=17 weeks) and duration of follow-up (median=40 months) were comparable in both treatment arms. A median of 6 cycles was received by patients in both treatment arms with 14% of subjects in the VcR-CAP group and 17% of patients in the R-CHOP group receiving 2 additional cycles. The majority of the patients in both groups completed treatment, 80% in the VcR-CAP group and 82% in the R-CHOP group. Efficacy results are presented in Table 16:</p><p><em>Table 16: Efficacy results from study LYM-3002</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy endpoint</strong></p></td><td style="vertical-align:top"><p><strong>VcR-CAP</strong></p></td><td style="vertical-align:top"><p><strong>R-CHOP</strong></p></td><td rowspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>n: ITT patients</p></td><td style="vertical-align:top"><p><u>243</u></p></td><td style="vertical-align:top"><p>244</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Progression free survival (IRC)<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Events n (%)</p></td><td style="vertical-align:top"><p>133 (54.7%)</p></td><td style="vertical-align:top"><p>165 (67.6%)</p></td><td rowspan="2" style="vertical-align:top"><p>HR<sup>b</sup>&nbsp;(95% CI)=0.63 (0.50; 0.79)</p><p>p-value<sup>d</sup>&nbsp;&lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>c</sup>(95% CI) (months)</p></td><td style="vertical-align:top"><p>24.7 (19.8; 31.8)</p></td><td style="vertical-align:top"><p>14.4 (12; 16.9)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Response rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>n: response-evaluable patients</p></td><td style="vertical-align:top"><p>229</p></td><td style="vertical-align:top"><p>228</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Overall complete response (CR+CRu)</em><sup>f</sup><em>&nbsp;n(%)</em></p></td><td style="vertical-align:top"><p>122 (53.3%)</p></td><td style="vertical-align:top"><p>95 (41.7%)</p></td><td style="vertical-align:top"><p>OR<sup>e</sup>&nbsp;(95% CI)=1.688 (1.148; 2.481)</p><p>p-value<sup>g</sup>=0.007</p></td></tr><tr><td style="vertical-align:top"><p><em>Overall response (CR+CRu+PR)<sup>h</sup>&nbsp;n(%)</em></p></td><td style="vertical-align:top"><p>211 (92.1%)</p></td><td style="vertical-align:top"><p>204 (89.5%)</p></td><td style="vertical-align:top"><p>OR<sup>e</sup>&nbsp;(95% CI)<strong>=</strong>1.428 (0.749; 2.722)</p><p>p-value<sup>g</sup><strong>=</strong>0.275</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Based on Independent Review Committee (IRC) assessment (radiological data only).</p><p><sup>b</sup>&nbsp;Hazard ratio estimate is based on a Cox&#39;s model stratified by IPI risk and stage of disease. A hazard ratio &lt; 1 indicates an advantage for VcR-CAP.</p><p><sup>c</sup>&nbsp;Based on Kaplan-Meier product limit estimates.</p><p><sup>d</sup>&nbsp;Based on Log rank test stratified with IPI risk and stage of disease.</p><p><sup>e</sup>&nbsp;Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors. An odds ratio (OR) &gt; 1 indicates an advantage for VcR-CAP.</p><p><sup>f</sup>&nbsp;Include all CR+CRu, by IRC, bone marrow and LDH.</p><p><sup>g</sup>&nbsp;P-value from the Cochran Mantel-Haenszel chi-square test, with IPI and stage of disease as stratification factors.</p><p><sup>h</sup>&nbsp;Include all radiological CR+CRu+PR by IRC regardless the verification by bone marrow and LDH.</p><p>CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response; CI=Confidence Interval, HR=Hazard Ratio; OR=Odds Ratio; ITT=Intent to Treat</p><p>Median PFS by investigator assessment was 30.7 months in the VcR-CAP group and 16.1 months in the R-CHOP group (Hazard Ratio [HR]=0.51; p &lt; 0.001). A statistically significant benefit (p &lt; 0.001) in favour of the VcR-CAP treatment group over the R-CHOP group was observed for TTP (median 30.5 versus 16.1 months), TNT (median 44.5 versus 24.8 months) and TFI (median 40.6 versus 20.5 months). The median duration of complete response was 42.1 months in the VcR-CAP group compared with 18 months in the R-CHOP group. The duration of overall response was 21.4 months longer in the VcR-CAP group (median 36.5 months versus 15.1 months in the R-CHOP group). The final analysis for OS was performed after a median follow-up of 82 months. Median OS was 90.7 months for the VcR-CAP group compared with 55.7 months for the R-CHOP group (HR=0.66; p=0.001). The observed final median difference in the OS between the 2 treatment groups was 35 months.</p><p><u>Patients with previously treated light-chain (AL) Amyloidosis</u></p><p>An open label non randomised Phase I/II study was conducted to determine the safety and efficacy of BORVIX in patients with previously treated light-chain (AL) Amyloidosis. No new safety concerns were observed during the study, and in particular BORVIX did not exacerbate target organ damage (heart, kidney and liver). In an exploratory efficacy analysis, a 67.3% response rate (including a 28.6% CR rate) as measured by hematologic response (M-protein) was reported in 49 evaluable patients treated with the maximum allowed doses of 1.6 mg/m<sup>2</sup>&nbsp;weekly and 1.3 mg/m<sup>2</sup>&nbsp;twice-weekly. For these dose cohorts, the combined 1-year survival rate was 88.1%.</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with BORVIX in all subsets of the paediatric population in multiple myeloma and in mantle cell lymphoma (see section 4.2 for information on paediatric use).</p><p>A Phase II, single-arm activity, safety, and pharmacokinetic trial conducted by the Children&#39;s Oncology Group assessed the activity of the addition of bortezomib to multi-agent re-induction chemotherapy in paediatric and young adult patients with lymphoid malignancies (pre-B cell acute lymphoblastic leukemia [ALL], T-cell ALL, and T-cell lymphoblastic lymphoma [LL]). An effective re-induction multi-agent chemotherapy regimen was administered in 3 blocks. BORVIX was administered only in Blocks 1 and 2 to avoid potential overlapping toxicities with coadministered drugs in Block 3.</p><p>Complete response (CR) was evaluated at the end of Block 1. In B-ALL patients with relapse within 18 months of diagnosis (n = 27) the CR rate was 67% (95% CI: 46, 84); the 4-month event free survival rate was 44% (95% CI: 26, 62). In B-ALL patients with relapse 18-36 months from diagnosis (n = 33) the CR rate was 79% (95% CI: 61, 91) and the 4-month event free survival rate was 73% (95% CI: 54, 85). The CR rate in first-relapsed T-cell ALL patients (n = 22) was 68% (95% CI: 45, 86) and the 4-month event free survival rate was 67% (95% CI: 42, 83). The reported efficacy data are considered inconclusive (see section 4.2).</p><p>There were 140 patients with ALL or LL enrolled and evaluated for safety; median age was 10 years (range 1 to 26). No new safety concerns were observed when BORVIX was added to the standard pediatric pre B cell ALL chemotherapy backbone. The following adverse reactions (Grade &ge; 3) were observed at a higher incidence in the BORVIX containing treatment regimen as compared with a historical control study in which the backbone regimen was given alone: in Block 1 peripheral sensory neuropathy (3% versus 0%); ileus (2.1% versus 0%); hypoxia (8% versus 2%). No information on possible sequelae or rates of peripheral neuropathy resolution were available in this study. Higher incidences were also noted for infections with Grade &ge; 3 neutropenia (24% versus 19% in Block 1 and 22% versus 11% in Block 2), increased ALT (17% versus 8% in Block 2), hypokalaemia (18% versus 6% in Block 1 and 21% versus 12% in Block 2) and hyponatraemia (12% versus 5% in Block 1 and 4% versus 0 in Block 2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following intravenous bolus administration of a 1.0 mg/m<sup>2</sup>&nbsp;and 1.3 mg/m<sup>2</sup>&nbsp;dose to 11 patients with multiple myeloma and creatinine clearance values greater than 50 ml/min, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/ml, respectively. In subsequent doses, mean maximum observed plasma concentrations ranged from 67 to 106 ng/ml for the 1.0 mg/m<sup>2</sup>&nbsp;dose and 89 to 120 ng/ml for the 1.3 mg/m<sup>2</sup>&nbsp;dose.</p><p>Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m<sup>2</sup>&nbsp;dose to patients with multiple myeloma (n=14 in the intravenous group, n=17 in the subcutaneous group), the total systemic exposure after repeat dose administration (AUC<sub>last</sub>) was equivalent for subcutaneous and intravenous administrations. The C<sub>max</sub>&nbsp;after subcutaneous administration (20.4 ng/ml) was lower than intravenous (223 ng/ml). The AUC<sub>last</sub>&nbsp;geometric mean ratio was 0.99 and 90% confidence intervals were 80.18%-122.80%.</p><p><u>Distribution</u></p><p>The mean distribution volume (V<sub>d</sub>) of bortezomib ranged from 1,659 l to 3,294 l following single- or repeated-dose intravenous administration of 1.0 mg/m<sup>2</sup>&nbsp;or 1.3 mg/m<sup>2</sup>&nbsp;to patients with multiple myeloma. This suggests that bortezomib distributes widely to peripheral tissues. Over a bortezomib concentration range of 0.01 to 1.0 &mu;g/ml, the&nbsp;<em>in vitro</em>&nbsp;protein binding averaged 82.9% in human plasma. The fraction of bortezomib bound to plasma proteins was not concentration-dependent.</p><p><u>Biotransformation</u></p><p><em>In vitro</em>&nbsp;studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolised via cytochrome P450 enzymes, 3A4, 2C19, and 1A2. The major metabolic pathway is deboronation to form two deboronated metabolites that subsequently undergo hydroxylation to several metabolites. Deboronated-bortezomib metabolites are inactive as 26S proteasome inhibitors.</p><p><u>Elimination</u></p><p>The mean elimination half-life (t<sub>1/2</sub>) of bortezomib upon multiple dosing ranged from 40-193 hours. Bortezomib is eliminated more rapidly following the first dose compared to subsequent doses. Mean total body clearances were 102 and 112 l/h following the first dose for doses of 1.0 mg/m<sup>2</sup>&nbsp;and 1.3 mg/m<sup>2</sup>, respectively, and ranged from 15 to 32 l/h and 18 to 32 l/h following subsequent doses for doses of 1.0 mg/m<sup>2</sup>&nbsp;and 1.3 mg/m<sup>2</sup>, respectively.</p><p><u>Special populations</u></p><p><em>Hepatic impairment</em></p><p>The effect of hepatic impairment on the pharmacokinetics of bortezomib was assessed in a Phase I study during the first treatment cycle, including 61 patients primarily with solid tumors and varying degrees of hepatic impairment at bortezomib doses ranging from 0.5 to 1.3 mg/m<sup>2</sup>.</p><p>When compared to patients with normal hepatic function, mild hepatic impairment did not alter dose-normalised bortezomib AUC. However, the dose-normalised mean AUC values were increased by approximately 60% in patients with moderate or severe hepatic impairment. A lower starting dose is recommended in patients with moderate or severe hepatic impairment, and those patients should be closely monitored (see section 4.2, Table 6).</p><p><em>Renal impairment</em></p><p>A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCL) into the following groups: Normal (CrCL &ge; 60 ml/min/1.73 m<sup>2</sup>, n=12), Mild (CrCL=40-59 ml/min/1.73 m<sup>2</sup>, n=10), Moderate (CrCL=20-39 ml/min/1.73 m<sup>2</sup>, n=9), and Severe (CrCL &lt; 20 ml/min/1.73 m<sup>2</sup>, n=3). A group of dialysis patients who were dosed after dialysis was also included in the study (n=8). Patients were administered intravenous doses of 0.7 to 1.3 mg/m<sup>2</sup>&nbsp;of BORVIX twice weekly. Exposure of BORVIX (dose-normalised AUC and C<sub>max</sub>) was comparable among all the groups (see section 4.2).</p><p><em>Age</em></p><p>The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m<sup>2</sup>&nbsp;doses to 104 pediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). Based on a population pharmacokinetic analysis, clearance of bortezomib increased with increasing body surface area (BSA). Geometric mean (%CV) clearance was 7.79 (25%) L/hr/m<sup>2</sup>, volume of distribution at steady-state was 834 (39%) L/m<sup>2</sup>, and the elimination half-life was 100 (44%) hours. After correcting for the BSA effect, other demographics such as age, body weight and sex did not have clinically significant effects on bortezomib clearance. BSA-normalized clearance of bortezomib in pediatric patients was similar to that observed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bortezomib was positive for clastogenic activity (structural chromosomal aberrations) in the&nbsp;<em>in vitro</em>&nbsp;chromosomal aberration assay using Chinese hamster ovary (CHO) cells at concentrations as low as 3.125 &mu;g/ml, which was the lowest concentration evaluated. Bortezomib was not genotoxic when tested in the&nbsp;<em>in vitro</em>&nbsp;mutagenicity assay (Ames assay) and&nbsp;<em>in vivo</em>&nbsp;micronucleus assay in mice.</p><p>Developmental toxicity studies in the rat and rabbit have shown embryo-fetal lethality at maternally toxic doses, but no direct embryo-foetal toxicity below maternally toxic doses. Fertility studies were not performed but evaluation of reproductive tissues has been performed in the general toxicity studies. In the 6-month rat study, degenerative effects in both the testes and the ovary have been observed. It is, therefore, likely that bortezomib could have a potential effect on either male or female fertility. Peri- and postnatal development studies were not conducted.</p><p>In multi-cycle general toxicity studies conducted in the rat and monkey, the principal target organs included the gastrointestinal tract, resulting in vomiting and/or diarrhoea; haematopoietic and lymphatic tissues, resulting in peripheral blood cytopenias, lymphoid tissue atrophy and haematopoietic bone marrow hypocellularity; peripheral neuropathy (observed in monkeys, mice and dogs) involving sensory nerve axons; and mild changes in the kidneys. All these target organs have shown partial to full recovery following discontinuation of treatment.</p><p>Based on animal studies, the penetration of bortezomib through the blood-brain barrier appears to be limited, if any and the relevance to humans is unknown.</p><p>Cardiovascular safety pharmacology studies in monkeys and dogs show that intravenous doses approximately two to three times the recommended clinical dose on a mg/m<sup>2</sup>&nbsp;basis are associated with increases in heart rate, decreases in contractility, hypotension and death. In dogs, the decreased cardiac contractility and hypotension responded to acute intervention with positive inotropic or pressor agents. Moreover, in dog studies, a slight increase in the corrected QT interval was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol (E 421)</p><p>Tert butyl alcohol</p><p>Nitrogen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial

36 months

Reconstituted solution

The reconstituted solution should be used immediately after preparation. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. However, the chemical and physical in-use stability of the reconstituted solution has been demonstrated for 8 hours at 25°C stored in the original vial and/or a syringe. The total storage time for the reconstituted medicinal product should not exceed 8 hours prior to administration.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25 C</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bortezomib for Injection is supplied as an individually cartoned 10 mL type I glass vial with a 13 mm rubber stopper and a 13 mm aluminum-plastic cap containing 3.5 mg of Bortezomib as a white to off-white cake or powder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General precautions</u></p><p>Bortezomib is a cytotoxic agent. Therefore, caution should be used during handling and preparation of BORVIX. Use of gloves and other protective clothing to prevent skin contact is recommended.</p><p><strong>Aseptic technique</strong>&nbsp;must be strictly observed throughout the handling of BORVIX, since it contains no preservative.</p><p>There have been fatal cases of inadvertent intrathecal administration of BORVIX. BORVIX 1 mg powder for solution for injection is for intravenous use only, while BORVIX 3.5 mg powder for solution for injection is for intravenous or subcutaneous use. BORVIX should not be administered intrathecally.</p><p><u>Instructions for reconstitution</u></p><p>BORVIX must be reconstituted by a healthcare professional.</p><p><em>Intravenous injection</em></p><p>Each 10 ml vial of BORVIX must be carefully reconstituted with 3.5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper. Dissolution of the lyophilised powder is completed in less than 2 minutes.</p><p>After reconstitution, each ml solution contains 1 mg bortezomib. The reconstituted solution is clear and colourless, with a final pH of 4 to 7.</p><p>The reconstituted solution must be inspected visually for particulate matter and discolouration prior to administration. If any discolouration or particulate matter is observed, the reconstituted solution must be discarded.</p><p><em>Subcutaneous injection</em></p><p>Each 10 ml vial of BORVIX must be carefully reconstituted with 1.4 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper. Dissolution of the lyophilised powder is completed in less than 2 minutes.</p><p>After reconstitution, each ml solution contains 2.5 mg bortezomib. The reconstituted solution is clear and colourless, with a final pH of 4 to 7. The reconstituted solution must be inspected visually for particulate matter and discolouration prior to administration. If any discolouration or particulate matter is observed, the reconstituted solution must be discarded.</p><p><u>Disposal</u></p><p>BORVIX is for single use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov-19
SPC-016-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>